Expression of the PD-1 antigen on the surface of stimula

International Immunology

8, 765-772

DOI: 10.1093/intimm/8.5.765

Citation Report

#	Article	IF	Citations
1	Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4â€“CD8â€“) thymocytes. International Immunology, 1996, 8, 773-780.	4.0	227
2	The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene, 1997, 197, 177-187.	2.2	99
3	PD-1. , 1997, , 579-580.		0
4	Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO Journal, 1998, 17, 2319-2333.	7.8	265
5	Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. International Immunology, 1998, 10, 1563-1572.	4.0	425
6	Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity, 1999, 11, 141-151.	14.3	2,336
7	16.ç³¸çƒä½“è…Žç‚Ž, é–¢ç¯€ç‚Žç™ºç—‡ã«ãŠã‘ã‚‹PD-1ã®æ©Ÿèƒ½ã«ã¤ã„ã¦. Proceedings of the Japanese Society of Animal Models for Hu	0.0	0
8	Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Current Opinion in Immunology, 2000, 12, 307-315.	5.5	114
9	Modulatory effect of 7-thia-8-oxoguanosine on proliferation of rat thymocytes in vitro stimulated with concanavalin A. International Journal of Immunopharmacology, 2000, 22, 203-212.	1.1	19
10	Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 2000, 192, 1027-1034.	8.5	4,394
11	Facilitation of Î² Selection and Modification of Positive Selection in the Thymus of Pd-1â€“Deficient Mice. Journal of Experimental Medicine, 2000, 191, 891-898.	8.5	177
12	Chapter 18 Model cell lines for the study of apoptosis in vitro. Methods in Cell Biology, 2001, 66, 417-436.	1.1	26
13	The expanding world of co-stimulation: the two-signal model revisited. Trends in Immunology, 2001, 22, 217-223.	6.8	180
14	PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends in Immunology, 2001, 22, 265-268.	6.8	428
15	The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nature Immunology, 2001, 2, 203-209.	14.5	372
16	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2001, 2, 261-268.	14.5	2,504
17	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nature Immunology, 2001, 2, 1174-1182.	14.5	250
18	CD4+CD25high Regulatory Cells in Human Peripheral Blood. Journal of Immunology, 2001, 167, 1245-1253.	0.8	1,655

#	Article	IF	Citations
19	Constitutive Association of SHP-1 with Leukocyte-Associated Ig-Like Receptor-1 in Human T Cells. Journal of Immunology, 2001, 166, 1763-1770.	0.8	65
20	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13866-13871.	7.1	732
21	Targeting T cell costimulation in autoimmune disease. Expert Opinion on Therapeutic Targets, 2002, 6, 275-289.	3.4	46
22	Expression of Programmed Death 1 Ligands by Murine T Cells and APC. Journal of Immunology, 2002, 169, 5538-5545.	0.8	831
23	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12293-12297.	7.1	2,563
24	Programmed Death-1 Targeting Can Promote Allograft Survival. Journal of Immunology, 2002, 169, 6546-6553.	0.8	219
25	The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses. Annual Review of Immunology, 2002, 20, 29-53.	21.8	792
26	T-Cell costimulatory pathways relevant to transplant rejection and tolerance. Transplantation Reviews, 2002, 16, 205-219.	2.9	4
27	CTLA-4 regulates cell cycle progression during a primary immune response. European Journal of Immunology, 2002, 32, 366-373.	2.9	115
28	PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. European Journal of Immunology, 2002, 32, 634.	2.9	612
29	Negative co-receptors on lymphocytes. Current Opinion in Immunology, 2002, 14, 391-396.	5.5	152
30	New regulatory co-receptors: inducible co-stimulator and PD-1. Current Opinion in Immunology, 2002, 14, 779-782.	5.5	221
31	Microanatomical localization of PD-1 in human tonsils. Immunology Letters, 2002, 83, 215-220.	2.5	69
32	Protect the killer: CTLs need defenses against the tumor. Nature Medicine, 2002, 8, 787-789.	30.7	22
33	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 2002, 8, 793-800.	30.7	4,217
34	The B7â€“CD28 superfamily. Nature Reviews Immunology, 2002, 2, 116-126.	22.7	1,513
35	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunology Letters, 2002, 84, 57-62.	2.5	249
36	Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation. Immunologic Research, 2003, 28, 49-60.	2.9	32

#	Article	IF	Citations
37	Immunology of B7-H1 and Its Roles in Human Diseases. International Journal of Hematology, 2003, 78, 321-328.	1.6	34
38	Modulation of costimulation to enhance tumor immunity. Cancer Immunology, Immunotherapy, 2003, 52, 663-669.	4.2	18
39	B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine, 2003, 81, 281-287.	3.9	249
40	Negative T cell costimulation and islet tolerance. Diabetes/Metabolism Research and Reviews, 2003, 19, 179-185.	4.0	19
41	Preferential contribution of B7â€H1 to programmed deathâ€1â€mediated regulation of haptenâ€specific allergic inflammatory responses. European Journal of Immunology, 2003, 33, 2773-2782.	2.9	119
42	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 2003, 33, 2706-2716.	2.9	551
43	A phenotypically distinct subset of immature B cells exhibits partial activation, increased survival, and preferential expression of VhS107. European Journal of Immunology, 2003, 33, 3398-3408.	2.9	11
44	B cell inhibitory receptors and autoimmunity. Immunology, 2003, 108, 263-273.	4.4	93
45	NIM-R7, a novel marker for resting B1 and marginal-zone B lymphocytes, is also expressed on activated T and B cells. Immunology, 2003, 109, 232-237.	4.4	2
46	Blockade of B7-H1 improves myeloid dendritic cellâ€“mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	30.7	1,157
47	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Allergy and Clinical Immunology, 2003, 112, 837-849.	2.9	50
48	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1. Biology of Reproduction, 2003, 68, 1496-1504.	2.7	189
49	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. Journal of Experimental Medicine, 2003, 198, 63-69.	8.5	697
50	Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochemical and Biophysical Research Communications, 2003, 307, 672-677.	2.1	181
51	Finding genes for SLE: complex interactions and complex populations. Journal of Autoimmunity, 2003, 21, 117-120.	6.5	8
52	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. Journal of Immunology, 2003, 171, 4156-4163.	0.8	163
53	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. Journal of Experimental Medicine, 2003, 197, 1083-1091.	8.5	259
54	B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy. Journal of Immunology, 2003, 170, 3637-3644.	0.8	242

#	Article	IF	Citations
55	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-Î³-Dependent Mechanism. Journal of Immunology, 2003, 171, 1272-1277.	0.8	305
56	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	8.5	461
57	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. Journal of Experimental Medicine, 2003, 198, 39-50.	8.5	353
58	T Cell Rewiring in Differentiation and Disease. Journal of Immunology, 2003, 171, 3325-3331.	0.8	57
59	Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6718-6723.	7.1	22
60	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. Journal of Immunology, 2003, 170, 1257-1266.	0.8	842
61	Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells. Journal of Immunology, 2003, 171, 4574-4581.	0.8	99
62	Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses. Journal of Immunology, 2003, 170, 711-718.	0.8	248
63	T cell costimulatory pathways: blockade for autoimmunity. Expert Opinion on Biological Therapy, 2003, 3, 227-236.	3.1	28
64	BOOSTING T CELL COSTIMULATION IN CANCER: THE POSSIBILITIES SEEM ENDLESS. International Reviews of Immunology, 2003, 22, 173-194.	3.3	10
65	Stimulating PD-1???negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival1. Transplantation, 2003, 76, 994-999.	1.0	140
66	PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. International Immunology, 2004, 17, 133-144.	4.0	413
67	B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clinical Cancer Research, 2004, 10, 5094-5100.	7.0	633
68	Refolding and Characterization of Recombinant Human GST-PD-1 Fusion Protein Expressed in Escherichia coli. Acta Biochimica Et Biophysica Sinica, 2004, 36, 141-146.	2.0	9
69	B7-DC Regulates Asthmatic Response by an IFN-Î³-Dependent Mechanism. Journal of Immunology, 2004, 172, 2530-2541.	0.8	136
70	Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2057-2062.	2.4	88
71	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. Journal of Immunology, 2004, 173, 945-954.	0.8	989
72	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. Journal of Immunology, 2004, 172, 5774-5781.	0.8	24

#	Article	IF	Citations
73	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10691-10696.	7.1	556
74	Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. International Immunology, 2004, 16, 1181-1188.	4.0	27
75	Co-inhibitory molecules of the B7â€“CD28 family in the control of T-cell immunity. Nature Reviews Immunology, 2004, 4, 336-347.	22.7	1,110
76	Core-binding factors in hematopoiesis and immune function. Oncogene, 2004, 23, 4238-4248.	5.9	216
77	The candidate gene approach: have murine models informed the study of human SLE?. Clinical and Experimental Immunology, 2004, 137, 1-7.	2.6	12
78	PD-1 ligands, negative regulators for activation of naÃ¯ve, memory, and recently activated human CD4+ T cells. Cellular Immunology, 2004, 230, 89-98.	3.0	64
79	Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies. Human Genetics, 2004, 115, 393-8.	3.8	37
80	Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking?. Immunology Letters, 2004, 93, 109-113.	2.5	53
81	Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 770-775.	6.7	148
82	Paradoxical role of programmed deathâ€1 ligandâ€„2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. European Journal of Immunology, 2004, 34, 3326-3336.	2.9	47
83	Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology, 2004, 40, 1312-1321.	7.3	277
84	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunology Letters, 2004, 94, 215-222.	2.5	67
85	The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology, 2004, 126, 1347-1357.	1.3	141
86	The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone, 2004, 35, 1059-1068.	2.9	28
87	PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3Î¶ signalosome and downstream signaling to PKCÎ¸. FEBS Letters, 2004, 574, 37-41.	2.8	643
88	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. Immunity, 2004, 20, 337-347.	14.3	331
89	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. Immunity, 2004, 20, 529-538.	14.3	202
90	Programmed death-1â€“programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation, 2004, 77, 6-12.	1.0	34

#	Article	IF	Citations
91	Naive CD4+ Cells from Cord Blood Can Generate Competent Th Effector Cells. Transplantation, 2005, 80, 850-858.	1.0	12
93	THE B7 FAMILY REVISITED. Annual Review of Immunology, 2005, 23, 515-548.	21.8	2,104
94	PD-L2+ dendritic cells and PD-1+ CD4+ T cells in schistosomiasis correlate with morbidity. Parasite Immunology, 2005, 27, 45-53.	1.5	20
95	Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. Clinical and Experimental Allergy, 2005, 35, 1521-1534.	2.9	18
96	B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature Immunology, 2005, 6, 90-98.	14.5	543
97	Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nature Immunology, 2005, 6, 280-286.	14.5	478
98	Immunotherapy for pancreatic cancer â€" science driving clinical progress. Nature Reviews Cancer, 2005, 5, 459-467.	28.4	180
99	Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain1. Acta Pharmacologica Sinica, 2005, 26, 462-468.	6.1	59
100	The B7/CD28 costimulatory family in autoimmunity. Immunological Reviews, 2005, 204, 128-143.	6.0	129
101	Pre-B cell loss in senescence coincides with preferential development of immature B cells characterized by partial activation and altered Vh repertoire. Experimental Gerontology, 2005, 40, 67-79.	2.8	14
102	Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. European Journal of Immunology, 2005, 35, 3545-3560.	2.9	28
103	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunology, Immunotherapy, 2005, 54, 307-314.	4.2	509
104	Dendritic cell-mediated T cell polarization. Seminars in Immunopathology, 2005, 26, 289-307.	4.0	296
105	The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine, 2005, 83, 193-202.	3.9	69
107	Immune Modulations. , 2005, , 475-490.		0
108	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Frontiers in Bioscience - Landmark, 2005, 10, 2856.	3.0	55
109	Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 3408-3415.	0.8	164
110	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1747-1767.	4.0	56

#	Article	IF	Citations
111	Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-Î³-Induced Nitric Oxide Production. Journal of Immunology, 2005, 175, 1586-1592.	0.8	129
112	A Class I Transgene Reveals Regulatory Events on Chromosome 1 Marking Peripheral T Cell Differentiation and Memory. Journal of Immunology, 2005, 174, 7564-7572.	0.8	1
113	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Biology, 2005, 25, 9543-9553.	2.3	1,609
114	Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 6648-6656.	0.8	139
115	THE NOD MOUSE: A Model of Immune Dysregulation. Annual Review of Immunology, 2005, 23, 447-485.	21.8	949
116	The genetics of shared autoimmunity. Autoimmunity, 2005, 38, 205-208.	2.6	11
117	High incidence of spontaneous autoimmune thyroiditis in immunocompetent self-reactive human T cell receptor transgenic mice. Journal of Autoimmunity, 2005, 24, 85-91.	6.5	18
118	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clinical Immunology, 2005, 115, 184-191.	3.2	86
119	Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Current Opinion in Pharmacology, 2005, 5, 424-430.	3.5	32
120	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Letters, 2005, 579, 6259-6264.	2.8	35
121	Various Costimulatory Pathways Are Essential for Induction of Regulatory Cells by Intratracheal Delivery of Alloantigen. Transplantation Proceedings, 2005, 37, 1934-1936.	0.6	8
122	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Research and Therapy, 2006, 8, R163.	3.5	70
123	Immunology of Pregnancy. , 2006, , .		11
124	Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clinical Immunology, 2006, 118, 258-267.	3.2	55
125	Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: Multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine, 2006, 36, 148-159.	3.2	59
126	Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. Journal of Hepatology, 2006, 45, 468-472.	3.7	46
127	Negative costimulatory molecules: The proximal of regulatory T cells?. Medical Hypotheses, 2006, 67, 841-847.	1.5	1
128	Roles of genetic variations in signalling/immunoregulatory molecules in susceptibility to systemic lupus erythematosus. Seminars in Immunology, 2006, 18, 224-229.	5.6	14

#	Article	IF	Citations
129	CD4+PD-1+T Cells Acting as Regulatory Cells during the Induction of Anterior Chamber-Associated Immune Deviation. , 2006, 47, 4444.		40
131	Murine isolated lymphoid follicles contain follicular B lymphocytes with a mucosal phenotype. American Journal of Physiology - Renal Physiology, 2006, 291, G595-G604.	3.4	24
132	Contribution of B Cells to Autoimmune Pathogenesis. , 2006, , 461-501.		0
133	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. Cell Transplantation, 2006, 15, 105-119.	2.5	65
134	Gene Transfer of Programmed Death Ligand-1.Ig Prolongs Cardiac Allograft Survival. Transplantation, 2006, 82, 1733-1737.	1.0	42
135	B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. Journal of Viral Hepatitis, 2006, 13, 725-733.	2.0	32
136	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 2006, 12, 1198-1202.	30.7	1,376
137	T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO Journal, 2006, 25, 2623-2633.	7.8	204
138	T_H2 Cells in the Pathogenesis of Airway Remodeling: Regulatory T Cells a Plausible Panacea for Asthma. Immunologic Research, 2006, 35, 219-232.	2.9	43
139	The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. Seminars in Immunopathology, 2006, 28, 109-117.	4.0	12
140	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. Journal of Molecular Medicine, 2006, 84, 887-899.	3.9	24
141	Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunology Letters, 2006, 102, 222-228.	2.5	47
142	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. Journal of Neuroscience Research, 2006, 84, 370-378.	2.9	205
143	Highâ€level expression of B7â€H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergenâ€primed animals. Journal of Leukocyte Biology, 2006, 79, 686-695.	3.3	35
144	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.8	122
145	Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. British Journal of Ophthalmology, 2006, 90, 1040-1045.	3.9	28
146	T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1447-1456.	2.4	18
147	The Biochemical Mechanisms of T-Cell Anergy. Current Immunology Reviews, 2006, 2, 73-99.	1.2	0

#	Article	IF	Citations
148	Cutting Edge: Programed Death (PD) Ligand-1/PD-1 Interaction Is Required for CD8+ T Cell Tolerance to Tissue Antigens. Journal of Immunology, 2006, 177, 8291-8295.	0.8	123
150	Cutting Edge: B and T Lymphocyte Attenuator and Programmed Death Receptor-1 Inhibitory Receptors Are Required for Termination of Acute Allergic Airway Inflammation. Journal of Immunology, 2006, 176, 3909-3913.	0.8	84
151	BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation. Journal of Immunology, 2006, 176, 7354-7360.	0.8	168
152	Differential Effects of Costimulatory Pathway Modulation on Corneal Allograft Survival. , 2006, 47, 3417.		51
153	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3360-3365.	7.1	1,308
154	Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. Journal of Experimental Medicine, 2007, 204, 2321-2333.	8.5	57
155	PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver. Journal of Immunology, 2007, 178, 2714-2720.	0.8	214
156	PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection. Journal of Immunology, 2007, 179, 5204-5210.	0.8	176
157	Expression of PD-1, PD-L1, and PD-L2 in the Liver in Autoimmune Liver Diseases. American Journal of Gastroenterology, 2007, 102, 302-312.	0.4	69
158	T-cell co-stimulatory molecules: their role in allergic immune reactions. European Respiratory Journal, 2007, 29, 1246-1255.	6.7	39
159	General aspects of the genetics of SLE. Autoimmunity, 2007, 40, 550-559.	2.6	36
160	Histone Deacetylase 7 Functions as a Key Regulator of Genes Involved in both Positive and Negative Selection of Thymocytes. Molecular and Cellular Biology, 2007, 27, 5184-5200.	2.3	58
161	Master switches of T-cell activation and differentiation. European Respiratory Journal, 2007, 29, 804-812.	6.7	38
162	Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology, 2007, 19, 1223-1234.	4.0	207
163	Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovascular Research, 2007, 75, 158-167.	3.8	51
164	A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance. Journal of Immunology, 2007, 179, 5211-5219.	0.8	136
165	Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-Î² signaling in activated T lymphocytes. Blood, 2007, 109, 2944-2952.	1.4	14
166	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 2007, 110, 180-185.	1.4	209

#	Article	IF	Citations
167	New Approaches to the Prevention of Organ Allograft Rejection and Tolerance Induction. Transplantation, 2007, 84, S38-S41.	1.0	6
168	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. Current Opinion in HIV and AIDS, 2007, 2, 219-227.	3.8	17
169	PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. Aids, 2007, 21, 2005-2013.	2.2	151
170	Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Journal of Clinical Investigation, 2007, 117, 2570-2582.	8.2	698
171	Costimulatory receptors in jawed vertebrates: Conserved CD28, odd CTLA4 and multiple BTLAs. Developmental and Comparative Immunology, 2007, 31, 255-271.	2.3	79
172	Transcriptional Signals of T-cell and Corticosteroid-sensitive Genes Are Associated With Future Acute Cellular Rejection in Cardiac Allografts. Journal of Heart and Lung Transplantation, 2007, 26, 1255-1263.	0.6	28
173	PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology, 2007, 19, 813-824.	4.0	1,064
175	Understanding Gene Expression Patterns in Immune-Mediated Disorders. Journal of Immunotoxicology, 2007, 4, 201-207.	1.7	7
176	Leukocyteâ€“Renal Epithelial Cell Interactions Regulate Lupus Nephritis. Seminars in Nephrology, 2007, 27, 59-68.	1.6	11
178	Inhibitory Receptors and Autoimmunity in the Mouse. , 2007, , 261-273.		0
179	Regulatory Cells and Immunosuppressive Cytokines: Parasite-Derived Factors Induce Immune Polarization. Journal of Biomedicine and Biotechnology, 2007, 2007, 1-10.	3.0	14
180	Current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 196-211.	2.8	150
181	Transplant tolerance through costimulation blockade - are we there yet?. Frontiers in Bioscience - Landmark, 2007, 12, 2935.	3.0	6
182	Augmented expression of programmed deathâ€1 in both neoplastic and nonâ€neoplastic CD4⁺ Tâ€cells in adult Tâ€cell leukemia/lymphoma. International Journal of Cancer, 2007, 121, 2585-2590.	5.1	82
183	Programmed cell deathâ€„1 (PDâ€1) and its ligand PDâ€L1 are required for allograft tolerance. European Journal of Immunology, 2007, 37, 2983-2990.	2.9	68
184	Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. Tissue Antigens, 2007, 69, 145-153.	1.0	41
185	Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. Xenotransplantation, 2007, 14, 243-248.	2.8	14
186	From Tâ€cell activation signals to signaling control of antiâ€cancer immunity. Immunological Reviews, 2007, 220, 151-168.	6.0	69

#	Article	IF	Citations
187	Virusâ€based immunotherapy of cancer: what do we know and where are we going?. Apmis, 2007, 115, 1177-1193.	2.0	4
188	Intrahepatic expression of the coâ€stimulatory molecules programmed deathâ€1, and its ligands in autoimmune liver disease. Pathology International, 2007, 57, 485-492.	1.3	54
189	Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clinical Immunology, 2007, 125, 16-25.	3.2	111
190	Inhibitory costimulation and anti-tumor immunity. Seminars in Cancer Biology, 2007, 17, 288-298.	9.6	27
191	PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2007, 182, 124-134.	2.3	175
192	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. Journal of Neuroimmunology, 2007, 185, 75-86.	2.3	63
193	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunology, Immunotherapy, 2007, 56, 1173-1182.	4.2	413
194	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunology, Immunotherapy, 2007, 56, 739-745.	4.2	412
195	Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1. Journal of Clinical Immunology, 2007, 27, 117-130.	3.8	12
196	Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. Journal of Human Genetics, 2007, 52, 557-560.	2.3	27
197	Modulating Co-Stimulation. Neurotherapeutics, 2007, 4, 666-675.	4.4	8
198	Functional dichotomy of plasmacytoid dendritic cells: Antigenâ€specific activation of T cells versus production of typeâ€„I interferon. European Journal of Immunology, 2008, 38, 1822-1832.	2.9	51
199	PDâ€1 ligands expressed on myeloidâ€derived APC in the CNS regulate Tâ€cell responses in EAE. European Journal of Immunology, 2008, 38, 2706-2717.	2.9	103
200	In situ imaging reveals different responses by naÃ¯ve and memory CD8 T cells to late antigen presentation by lymph node DC after influenza virus infection. European Journal of Immunology, 2008, 38, 3304-3315.	2.9	36
201	PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 2008, 26, 677-704.	21.8	4,462
202	Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand Is Critical for the Induction of an Efficient Tumor Specific Immune Response. Cellular and Molecular Immunology, 2008, 5, 33-39.	10.5	9
203	PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transplant International, 2008, 21, ???-???.	1.6	40
204	Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation. Immunology, 2008, 123, 40-44.	4.4	68

#	Article	IF	Citations
205	Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newbornsâ€™ dendritic cells. Clinical Immunology, 2008, 126, 243-250.	3.2	52
206	CLTAâ€4 blockade in vivo promotes the generation of shortâ€lived effector CD8⁺ T cells and a more persistent central memory CD4⁺ T cell response. Journal of Medical Primatology, 2008, 37, 62-68.	0.6	7
208	The complex role of B7 molecules in tumor immunology. Trends in Molecular Medicine, 2008, 14, 550-559.	6.7	84
209	Interferon-sensitive response element (ISRE) is mainly responsible for IFN-Î±-induced upregulation of programmed death-1 (PD-1) in macrophages. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2008, 1779, 811-819.	1.9	75
210	B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochemical and Biophysical Research Communications, 2008, 365, 170-175.	2.1	47
211	Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. Journal of Immunology, 2008, 181, 116-125.	0.8	234
212	Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice. Journal of Immunology, 2008, 181, 2513-2521.	0.8	157
213	NFATc1 Regulates PD-1 Expression upon T Cell Activation. Journal of Immunology, 2008, 181, 4832-4839.	0.8	311
214	PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue. Journal of Immunology, 2008, 181, 5313-5322.	0.8	48
215	Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10483-10488.	7.1	176
216	Tumor-Induced Immune Suppression ofIn vivoEffector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor Î². Cancer Research, 2008, 68, 5432-5438.	0.9	66
218	Blockade of PD-1/B7-H1 Interaction Restores Effector CD8+ T Cell Responses in a Hepatitis C Virus Core Murine Model. Journal of Immunology, 2008, 180, 4875-4884.	0.8	56
219	Expression and Function of PDCD1 at the Human Maternal-Fetal Interface1. Biology of Reproduction, 2008, 79, 562-569.	2.7	79
220	The Programmed Death-1 and Interleukin-10 Pathways Play a Down-Modulatory Role in LP-BM5 Retrovirus-Induced Murine Immunodeficiency Syndrome. Journal of Virology, 2008, 82, 2456-2469.	3.4	16
221	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008, 111, 3635-3643.	1.4	438
222	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood, 2008, 112, 2149-2155.	1.4	63
224	PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro. , 2008, 49, 2518.		105
225	PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation. , 2009, 50, 273.		78

#	Article	IF	Citations
226	Soluble PD-1 is Associated with Aberrant Regulation of T Cells Activation in Aplastic Anemia. Immunological Investigations, 2009, 38, 408-421.	2.0	36
227	Binding of DC-HIL to Dermatophytic Fungi Induces Tyrosine Phosphorylation and Potentiates Antigen Presenting Cell Function. Journal of Immunology, 2009, 183, 5190-5198.	0.8	30
228	PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells. Journal of Immunology, 2009, 182, 2816-2826.	0.8	178
229	Recruitment of Sprouty1 to Immune Synapse Regulates T Cell Receptor Signaling. Journal of Immunology, 2009, 183, 7178-7186.	0.8	16
230	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. Journal of Immunology, 2009, 182, 6718-6726.	0.8	18
231	Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis. Ocular Immunology and Inflammation, 2009, 17, 47-55.	1.8	39
232	Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade. Journal of Immunology, 2009, 182, 2102-2112.	0.8	105
233	CD21/35 Promotes Protective Immunity to Streptococcus pneumoniae through a Complement-Independent but CD19-Dependent Pathway That Regulates PD-1 Expression. Journal of Immunology, 2009, 183, 3661-3671.	0.8	26
235	Ectopically expressed PIR-B on T cells constitutively binds to MHC class I and attenuates T helper type 1 responses. International Immunology, 2009, 21, 1151-1161.	4.0	10
236	Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. Human Reproduction, 2009, 24, 3160-3171.	0.9	63
237	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. International Journal of Oncology, 2009, 35, 741-9.	3.3	68
238	BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. Journal of Leukocyte Biology, 2009, 86, 41-51.	3.3	28
239	Antiâ€“Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factorâ€“Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors. Clinical Cancer Research, 2009, 15, 1623-1634.	7.0	174
240	Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous Sysyem Infection and Dampens Morbidity. Journal of Immunology, 2009, 182, 5430-5438.	0.8	70
241	Protective CD8 T Cell Memory Is Impaired during Chronic CD70-Driven Costimulation. Journal of Immunology, 2009, 182, 5352-5362.	0.8	42
242	PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo. Journal of Immunology, 2009, 182, 6682-6689.	0.8	184
243	Immune escape mechanisms of intraocular tumors. Progress in Retinal and Eye Research, 2009, 28, 329-347.	15.5	91
244	Maternal PD-1 regulates accumulation of fetal antigen-specific CD8+ T cells in pregnancy. Journal of Reproductive Immunology, 2009, 80, 12-21.	1.9	68

#	Article	IF	Citations
245	Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cellular Immunology, 2009, 258, 161-171.	3.0	15
246	Age-associated up-regulation of a negative co-stimulatory receptor PD-1 in mouse CD4+ T cells. Experimental Gerontology, 2009, 44, 517-522.	2.8	77
247	Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 2009, 58, 687-697.	4.2	99
248	Negative regulators of Tâ€cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunological Reviews, 2009, 229, 67-87.	6.0	150
249	Yinâ€“Yang of costimulation: crucial controls of immune tolerance and function. Immunological Reviews, 2009, 229, 88-100.	6.0	138
250	Costimulatory and coinhibitory receptors in antiâ€tumor immunity. Immunological Reviews, 2009, 229, 126-144.	6.0	246
251	Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells. Immunology Letters, 2009, 127, 39-47.	2.5	44
252	PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood, 2009, 113, 5811-5818.	1.4	179
253	The Inhibitory Co-Receptors: A Way to Save from Anergy the HIVSpecific T Cells. Current HIV Research, 2009, 7, 266-272.	0.5	16
254	Impact of changes in antigen level on CD38/PDâ€1 coâ€expression on HIVâ€specific CD8 T cells in chronic, untreated HIVâ€1 infection. Journal of Medical Virology, 2010, 82, 358-370.	5.0	31
255	Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver International, 2010, 30, 1379-1386.	3.9	39
256	The PDâ€1 pathway in tolerance and autoimmunity. Immunological Reviews, 2010, 236, 219-242.	6.0	1,902
257	Molecular cloning and expression analysis of bovine programmed death-1. Microbiology and Immunology, 2010, 54, 291-8.	1.4	17
258	Telbivudine preserves Tâ€helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. Journal of Viral Hepatitis, 2010, 17, 24-33.	2.0	16
259	Role Played by the Programmed Deathâ€1â€“Programmed Death Ligand Pathway during Innate Immunity againstMycobacterium tuberculosis. Journal of Infectious Diseases, 2010, 202, 524-532.	4.0	112
260	Inhibitory TCR Coreceptor PD-1 Is a Sensitive Indicator of Low-Level Replication of SIV and HIV-1. Journal of Immunology, 2010, 184, 476-487.	0.8	41
261	APCs Expressing High Levels of Programmed Death Ligand 2 Sustain the Development of CD4 T Cell Memory. Journal of Immunology, 2010, 185, 3149-3157.	0.8	7
262	B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function. Journal of Immunology, 2010, 185, 3140-3148.	0.8	64

#	Article	IF	Citations
263	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. Current Topics in Microbiology and Immunology, 2010, 344, 245-267.	1.1	44
264	T Follicular Helper Cells During Immunity and Tolerance. Progress in Molecular Biology and Translational Science, 2010, 92, 207-248.	1.7	43
265	PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. International Immunology, 2010, 22, 651-660.	4.0	189
266	Early Signals during CD8+ T Cell Priming Regulate the Generation of Central Memory Cells. Journal of Immunology, 2010, 185, 263-272.	0.8	108
267	Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice. Journal of Immunology, 2010, 184, 2337-2347.	0.8	73
268	Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2010, 146, 1382.	1.4	124
269	Enhanced Antiviral T Cell Function in the Absence of B7-H1 Is Insufficient To Prevent Persistence but Exacerbates Axonal Bystander Damage during Viral Encephalomyelitis. Journal of Immunology, 2010, 185, 5607-5618.	0.8	40
270	Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 447-454.	2.1	70
271	Programmed Death-1 Antibody Blocks Therapeutic Effects of T-Regulatory Cells in Cockroach Antigen-Induced Allergic Asthma. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 432-442.	2.9	38
272	Association of the CYP27B1 C(â^'1260)A Polymorphism with Autoimmune Addison's Disease. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 544-549.	1.2	26
273	Role of PD-1 in Regulating T-Cell Immunity. Current Topics in Microbiology and Immunology, 2010, 350, 17-37.	1.1	244
276	The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. Immunobiology, 2011, 216, 918-924.	1.9	15
277	B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology, 2011, 216, 1302-1310.	1.9	95
278	Functional and Epigenetic Studies Reveal Multistep Differentiation and Plasticity of InÂVitro-Generated and InÂVivo-Derived Follicular T Helper Cells. Immunity, 2011, 35, 622-632.	14.3	232
279	Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e23621.	2.5	148
280	Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1. Journal of Immunotherapy, 2011, 34, 297-306.	2.4	102
281	The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells. Journal of Oral Pathology and Medicine, 2011, 40, 525-532.	2.7	16
282	The role of the PDâ€1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences, 2011, 1217, 45-59.	3.8	290

#	Article	IF	Citations
283	Altered TNF-Î± and IFN-Î³ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infection, Genetics and Evolution, 2011, 11, 1624-1630.	2.3	26
284	Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discovery Today, 2011, 16, 733-740.	6.4	16
285	Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clinical and Experimental Metastasis, 2011, 28, 661-674.	3.3	23
286	Program death 1 (PD1) haplotyping in patients with breast carcinoma. Molecular Biology Reports, 2011, 38, 4205-4210.	2.3	39
287	Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. Clinical Rheumatology, 2011, 30, 1181-1187.	2.2	20
288	The effects of PDL-Ig on collagen-induced arthritis. Rheumatology International, 2011, 31, 513-519.	3.0	54
289	Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflammation Research, 2011, 60, 47-53.	4.0	57
290	Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology, 2011, 54, 216-228.	7.3	37
291	PDâ€‹1 and PDâ€Ł1 upregulation promotes CD8⁺ Tâ€€cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. International Journal of Cancer, 2011, 128, 887-896.	5.1	395
292	Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery, 2011, 2, 873-889.	2.2	20
293	PD-1 Signaling in HIV and Chronic Viral Infection â€“ Potential for Therapeutic Intervention?. Current Medicinal Chemistry, 2011, 18, 3971-3980.	2.4	15
294	Fighting with the Enemys Weapons? The Role of Costimulatory Molecules in HIV. Current Molecular Medicine, 2011, 11, 172-196.	1.3	4
295	Immunotherapy of Murine Retrovirus-Induced Acquired Immunodeficiency by CD4 T Regulatory Cell Depletion and PD-1 Blockade. Journal of Virology, 2011, 85, 13342-13353.	3.4	19
296	Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection. Journal of Immunology, 2011, 186, 6280-6286.	0.8	43
297	IFN-Î± Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. Journal of Immunology, 2011, 186, 2772-2779.	0.8	278
298	Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1. Infection and Immunity, 2011, 79, 1873-1881.	2.2	48
299	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	118
300	Molecular Mechanisms of Induction of Antigen-Specific Allograft Tolerance by Intranasal Peptide Administration. Journal of Immunology, 2011, 186, 5719-5728.	0.8	7

#	Article	IF	Citations
301	The Role of LAT in Increased CD8 ⁺ T Cell Exhaustion in Trigeminal Ganglia of Mice Latently Infected with Herpes Simplex Virus 1. Journal of Virology, 2011, 85, 4184-4197.	3.4	103
302	Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease. Journal of Immunology, 2012, 188, 724-734.	0.8	30
303	Coinhibitory Molecules in Autoimmune Diseases. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	39
304	Anti-Î³Î´ TCR antibody-expanded Î³Î´ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cellular and Molecular Immunology, 2012, 9, 34-44.	10.5	59
305	Programmed Death-1+ T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E934-E943.	3.6	106
306	B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets. Journal of Immunology, 2012, 189, 2338-2347.	0.8	44
307	Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction. Reviews on Recent Clinical Trials, 2012, 7, 10-23.	0.8	31
308	Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy. Blood, 2012, 119, 3073-3083.	1.4	76
309	Molecular Pathways: Next-Generation Immunotherapyâ€"Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research, 2012, 18, 6580-6587.	7.0	543
310	Role of the PD-1 Pathway in the Immune Response. American Journal of Transplantation, 2012, 12, 2575-2587.	4.7	348
311	Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10468-10473.	7.1	112
312	Application of Monoclonal Antibodies in a Sandwich Enzyme-Linked Immunosorbent Assay for Identification and Detection of Soluble Human B and T Lymphocyte Attenuator. Hybridoma, 2012, 31, 417-423.	0.4	4
313	Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice. Journal of Surgical Research, 2012, 176, e79-e87.	1.6	8
314	Tubular cell HIV-entry through apoptosed CD4 T cells: A novel pathway. Virology, 2012, 434, 68-77.	2.4	18
315	Znaczenie receptora programowanej Å›mierci 1 oraz jego ligandÃ³w w ukÅ‚adzie immunologicznym oraz nowotworach. Acta Haematologica Polonica, 2012, 43, 132-145.	0.3	11
316	Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation. Expert Opinion on Therapeutic Targets, 2012, 16, 783-789.	3.4	2
317	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Journal of Experimental Medicine, 2012, 209, 1201-1217.	8.5	864
318	Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice. Vaccine, 2012, 30, 758-766.	3.8	22

#	Article	IF	Citations
319	What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?. Annals of Oncology, 2012, 23, viii28-viii34.	1.2	44
320	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. Journal of Hepatology, 2012, 56, 1230-1238.	3.7	19
321	Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology, 2012, 217, 669-675.	1.9	49
322	Expression of prohibitins on the surface of activated T cells. Biochemical and Biophysical Research Communications, 2012, 420, 275-280.	2.1	26
323	Successful Vaccination Induces Multifunctional Memory T-Cell Precursors Associated With Early Control of Hepatitis C Virus. Gastroenterology, 2012, 143, 1048-1060.e4.	1.3	64
324	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leukemia and Lymphoma, 2012, 53, 2015-2023.	1.3	35
325	Polymorphisms in PDCD1 gene are not associated with aplastic anemia in Chinese Han population. Rheumatology International, 2012, 32, 3107-3112.	3.0	6
326	PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-Î³ Inducible Chemokines. Cancer Research, 2012, 72, 5209-5218.	0.9	351
327	Protocadherin-18 Is a Novel Differentiation Marker and an Inhibitory Signaling Receptor for CD8+ Effector Memory T Cells. PLoS ONE, 2012, 7, e36101.	2.5	17
328	Multiple Mechanisms of Immune Suppression by B Lymphocytes. Molecular Medicine, 2012, 18, 123-137.	4.4	109
329	CO-INHIBITORY MOLECULE PROGRAMMED DEATH-1 AND ITS LIGANDS: A NEW ALTERNATIVE THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION?. American Journal of Infectious Diseases, 2012, 8, 149-162.	0.2	0
330	Role of Inhibitory BCR Co-Receptors in Immunity. Infectious Disorders - Drug Targets, 2012, 12, 181-190.	0.8	50
331	CD28 Family and Chronic Rejection: â€œTo Belatacept...and Beyond!â€• Journal of Transplantation, 2012, 2012, 1-14.	0.5	3
332	B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World Journal of Gastroenterology, 2012, 18, 971.	3.3	46
333	HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Laboratory Investigation, 2012, 92, 295-304.	3.7	33
334	Study of CD4+CD8+ Double positive Tâ€lymphocyte phenotype and function in Indian patients infected with HIVâ€1. Journal of Medical Virology, 2012, 84, 845-856.	5.0	22
335	Tâ€follicular helper cell differentiation and the coâ€option of this pathway by nonâ€helper cells. Immunological Reviews, 2012, 247, 143-159.	6.0	76
336	Immune checkpoints in central nervous system autoimmunity. Immunological Reviews, 2012, 248, 122-139.	6.0	90

#	Article	IF	Citations
337	Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. Veterinary Research, 2013, 44, 59.	3.0	52
338	BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. Molecular Immunology, 2013, 56, 819-828.	2.2	34
340	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature Immunology, 2013, 14, 1212-1218.	14.5	783
341	Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients. Molecular Biology Reports, 2013, 40, 5833-5842.	2.3	23
342	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmunity Reviews, 2013, 12, 1091-1100.	5.8	213
343	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunology, Immunotherapy, 2013, 62, 1649-1662.	4.2	7
344	Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. , 2013, 1, 15.		58
345	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
346	Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure. Immunity, 2013, 39, 770-781.	14.3	571
347	Differing HLA types influence inhibitory receptor signalling in CMV-specific CD8+ T cells. Human Immunology, 2013, 74, 302-309.	2.4	2
348	Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery, 2013, 12, 130-146.	46.4	229
349	Adaptive resistance: A tumor strategy to evade immune attack. European Journal of Immunology, 2013, 43, 576-579.	2.9	17
350	Immunotherapy for Renal Cell Carcinoma. , 2013, , 279-301.		0
351	At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Journal of Leukocyte Biology, 2013, 94, 25-39.	3.3	317
352	In vivo imaging of graft-versus-host disease and graft-versus-leukemia. , 2013, , 59-81.		0
353	Manipulating the PD-1 pathway to improve immunity. Current Opinion in Immunology, 2013, 25, 381-388.	5.5	95
354	Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types. Journal of Immunology, 2013, 191, 4880-4888.	0.8	182
355	The Role of Interleukin-6 in the Expression of PD-1 and PDL-1 on Central Nervous System Cells following Infection with Theiler's Murine Encephalomyelitis Virus. Journal of Virology, 2013, 87, 11538-11551.	3.4	34

#	Article	IF	Citations
356	PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4+ T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes. Diabetes, 2013, 62, 2859-2869.	0.6	64
357	Immunotherapy in Lung Cancer: â€œB7-Bombersâ€•and Other New Developments. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 810-821.	2.1	6
358	From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases. BioMed Research International, 2013, 2013, 1-8.	1.9	9
359	PD-1 and CTLA-4 Mediated Inhibitory Signaling for T cell Exhaustion during Chronic Viral Infections. Journal of Clinical & Cellular Immunology, 2013, 01, .	1.5	3
360	Biologics in Dermatology. Pharmaceuticals, 2013, 6, 557-578.	3.8	9
361	T Cells and Costimulation in Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 473-482.	2.0	22
362	Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets. Advances in Bioscience and Biotechnology (Print), 2013, 04, 19-29.	0.7	14
363	PD-1 is a novel regulator of human B-cell activation. International Immunology, 2013, 25, 129-137.	4.0	261
364	The Frequency of CD127 ⁺ Hepatitis C Virus (HCV)-Specific T Cells but Not the Expression of Exhaustion Markers Predicts the Outcome of Acute HCV Infection. Journal of Virology, 2013, 87, 4772-4777.	3.4	50
365	PD-1 Regulates T Cell Proliferation in a Tissue and Subset-Specific Manner During Normal Mouse Pregnancy. Immunological Investigations, 2013, 42, 385-408.	2.0	20
366	Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. Biomarkers, 2013, 18, 532-541.	1.9	16
367	PD-L1/B7-H1 Regulates the Survival but Not the Function of CD8+ T Cells in Herpes Simplex Virus Type 1 Latently Infected Trigeminal Ganglia. Journal of Immunology, 2013, 190, 6277-6286.	0.8	30
368	Association between polymorphisms in PDCD1 gene and aplastic anemia in Chinese Han population. Leukemia and Lymphoma, 2013, 54, 2251-2254.	1.3	10
369	The co-receptor BTLA negatively regulates human VÎ³9VÎ´2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood, 2013, 122, 922-931.	1.4	87
370	Genes Involved in Type 1 Diabetes. , 2013, , .		0
371	The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease. PLoS ONE, 2013, 8, e60367.	2.5	14
372	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives. , 2013, , .		2
373	The nature of activatory and tolerogenic dendritic cell-derived signal II. Frontiers in Immunology, 2013, 4, 53.	4.8	91

#	Article	IF	Citations
374	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013, 4, 417.	4.8	62
375	Genes Involved in Type 1 Diabetes: An Update. Genes, 2013, 4, 499-521.	2.4	61
376	Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Network, 2013, 13, 184.	3.6	49
377	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal of Receptor, Ligand and Channel Research, 2014, , 1.	0.7	2
378	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. OncoTargets and Therapy, 2014, 7, 567.	2.0	206
379	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Frontiers in Cellular Neuroscience, 2014, 8, 228.	3.7	11
380	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Journal of Clinical Investigation, 2014, 124, 2246-2259.	8.2	892
381	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. Journal of Pigmentary Disorders, 2014, 01, .	0.2	0
382	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. , 2014, , .		4
383	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease. Journal of Immunology, 2014, 193, 2565-2573.	0.8	67
384	New antibody approaches to lymphoma therapy. Journal of Hematology and Oncology, 2014, 7, 58.	17.0	50
385	Essential Role of Program Death 1-Ligand 1 in Regulatory T-Cellâ€“Afforded Protection Against Bloodâ€“Brain Barrier Damage After Stroke. Stroke, 2014, 45, 857-864.	2.0	106
386	Malaria drives T cells to exhaustion. Frontiers in Microbiology, 2014, 5, 249.	3.5	70
387	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. Lung Cancer Management, 2014, 3, 175-190.	1.5	1
388	Immune Activation Is Associated With Increased Gut Microbial Translocation in Treatment-Naive, HIV-Infected Children in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 16-24.	2.1	27
389	Immune Cell Crosstalk in Obesity: A Key Role for Costimulation?. Diabetes, 2014, 63, 3982-3991.	0.6	98
390	The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. Modern Rheumatology, 2014, 24, 953-960.	1.8	10
391	Signals and pathways controlling regulatory T cells. Immunological Reviews, 2014, 258, 117-131.	6.0	48

#	Article	IF	Citations
392	Immunological in vivo effects of B7-H1 deficiency. Immunology Letters, 2014, 162, 273-286.	2.5	5
393	Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. Journal of Leukocyte Biology, 2014, 96, 397-410.	3.3	9
394	Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	146
395	Co-Inhibitory Pathways and Their Importance in Immune Regulation. Transplantation, 2014, 98, 3-14.	1.0	70
396	PD-1 as an Immune Modulatory Receptor. Cancer Journal (Sudbury, Mass), 2014, 20, 262-264.	2.0	62
397	CD8+Ã¢â‚¬â€°T-Cell Responses in Acute Hepatitis C Virus Infection. Frontiers in Immunology, 2014, 5, 266.	4.8	29
398	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. Journal of Hematology and Oncology, 2014, 7, 16.	17.0	6
399	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. European Urology, 2014, 65, 289-299.	1.9	113
400	Programmed death-1 (PD-1)-dependent functional impairment of CD4+ T cells in recurrent genital papilloma. Clinical and Experimental Medicine, 2014, 14, 305-313.	3.6	12
401	Programmed death-1 pathway in cancer and autoimmunity. Clinical Immunology, 2014, 153, 145-152.	3.2	218
402	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 2014, 28, 993-1000.	7.2	92
403	Type I IFN Induces Binding of STAT1 to Bcl6: Divergent Roles of STAT Family Transcription Factors in the T Follicular Helper Cell Genetic Program. Journal of Immunology, 2014, 192, 2156-2166.	0.8	95
404	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1-14.	3.4	38
405	Increased percentages of PD-1 on CD4⁺T cells is associated with higher INF-Î³ production and altered IL-17 production in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2014, 43, 307-313.	1.1	31
406	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant Tâ€lymphoproliferative disorders: brief review. Hematological Oncology, 2014, 32, 113-119.	1.7	21
407	Programmed death-1 (PD-1): A novel mechanism for understanding the acute immune deregulation in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2014, 177, 8-10.	1.7	6
408	Telomere shortening and immune activity in war veterans with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 275-283.	4.8	59
409	Characteristics of Î³Î´ T cells in Schistosoma japonicum-infected mouse mesenteric lymph nodes. Parasitology Research, 2014, 113, 3393-3401.	1.6	12

#	Article	IF	Citations
410	CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis jointsâ€"analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Research and Therapy, 2014, 16, R97.	3.5	109
411	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Antiâ€"PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	7.0	2,050
412	Up-regulated expression of PD-1 and its ligands during acute Classical Swine Fever virus infection in swine. Research in Veterinary Science, 2014, 97, 251-256.	1.9	14
413	VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy. Cancer Immunology Research, 2014, 2, 510-517.	3.4	187
414	Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. Cell Reports, 2014, 6, 625-632.	6.4	53
415	Loss of CD28 Expression by Liver-Infiltrating T Cells Contributes to Pathogenesis of Primary Sclerosing Cholangitis. Gastroenterology, 2014, 147, 221-232.e7.	1.3	81
416	Update on Immune Checkpoint Inhibitors in Lung Cancer. Cancer Control, 2014, 21, 80-89.	1.8	76
417	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2015, 46, 28-36.	3.3	69
418	Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model. Biological and Pharmaceutical Bulletin, 2015, 38, 1120-1125.	1.4	4
419	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.5	4
420	Programmed death 1 and its ligands do not limit experimental foreign antigenâ€induced immune complex glomerulonephritis. Nephrology, 2015, 20, 892-898.	1.6	4
421	Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis. OncoTargets and Therapy, 2015, 8, 3595.	2.0	33
422	Biomarkers of Response to Immune Modulatory Therapies in Cancer. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	1
423	Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment. Clinical Cancer Drugs, 2015, 2, 4-15.	0.3	0
424	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. Karger Kompass Onkologie, 2015, 2, 8-14.	0.0	0
425	Inhibitory Receptors Beyond T Cell Exhaustion. Frontiers in Immunology, 2015, 6, 310.	4.8	188
426	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget, 2015, 6, 14209-14219.	1.8	209
427	Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment. PLoS ONE, 2015, 10, e0119483.	2.5	35

#	Article	IF	Citations
428	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathogens, 2015, 11, e1005270.	4.7	41
429	Expression of PD-1 by CD4+CD25+CD127low Treg cells in the peripheral blood of lung cancer patients. OncoTargets and Therapy, 2015, 8, 1831.	2.0	12
430	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget, 2015, 6, 27359-27377.	1.8	242
431	T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?. Photochemical and Photobiological Sciences, 2015, 14, 1492-1509.	2.9	76
432	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	3.5	483
433	Introduction to Costimulation and Costimulatory Molecules. , 2015, , 1-43.		15
434	Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion. Digestive Diseases and Sciences, 2015, 60, 2662-2669.	2.3	12
435	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2908-2913.	1.3	18
436	Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay. AAPS Journal, 2015, 17, 976-987.	4.4	11
437	The PTEN pathway in T _{regs} is a critical driver of the suppressive tumor microenvironment. Science Advances, 2015, 1, e1500845.	10.3	167
438	Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunology Research, 2015, 3, 412-423.	3.4	381
439	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine, 2015, 13, 5.	4.4	73
440	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. Acta Haematologica, 2015, 134, 208-214.	1.4	18
441	Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44+CD62Lhigh IL-7R+ CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cellular and Molecular Immunology, 2015, 12, 456-465.	10.5	16
442	New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 2015, 36, 587-595.	8.7	158
443	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	6.4	27
444	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. Cancer Immunology Research, 2015, 3, 1279-1288.	3.4	3
445	Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities. Acta Haematologica, 2015, 133, 129-135.	1.4	8

#	Article	IF	Citations
446	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Review of Anticancer Therapy, 2015, 15, 509-523.	2.4	21
447	The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology, 2015, 123, 413-423.	2.9	15
448	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology, 2015, 12, 14.	2.0	119
449	Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. Journal of Leukocyte Biology, 2015, 97, 1101-1109.	3.3	36
451	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 973-983.	3.4	9
452	NF-Î¹B Regulates PD-1 Expression in Macrophages. Journal of Immunology, 2015, 194, 4545-4554.	0.8	134
453	Tissue Distribution of Memory T and B Cells in Rhesus Monkeys following Influenza A Infection. Journal of Immunology, 2015, 195, 4378-4386.	0.8	36
454	T-bet regulates differentiation of forkhead box protein 3+regulatory T cells in programmed cell death-1-deficient mice. Clinical and Experimental Immunology, 2015, 179, 197-209.	2.6	5
455	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306.	2.4	20
456	Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunology, 2015, 16, 39.	2.2	103
457	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjugate Chemistry, 2015, 26, 2062-2069.	3.6	139
458	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 41-50.	0.5	7
459	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Nonâ€“PD-1â€“Mediated Pathway. Journal of Immunology, 2015, 195, 3584-3595.	0.8	13
460	Kidney cancer and 2014: is innovation really over?. Future Oncology, 2015, 11, 1437-1449.	2.4	1
461	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy, 2015, 7, 1169-1186.	2.0	45
462	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	4.6	64
463	B7H1/CD80 Interaction Augments PD-1â€“Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. Journal of Immunology, 2015, 194, 560-574.	0.8	61
464	Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. British Journal of Dermatology, 2015, 172, 940-950.	1.5	52

#	Article	IF	Citations
465	Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2. Virology, 2015, 474, 94-104.	2.4	5
466	Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 2016, 10, 293.	1.8	47
467	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. Immune Network, 2016, 16, 134.	3.6	8
468	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	1.8	100
469	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	5.0	128
470	Development of Novel Immunotherapies for Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 1506.	4.1	22
471	Molecular and Cellular Characterization of Human CD8 T Suppressor Cells. Frontiers in Immunology, 2016, 7, 549.	4.8	33
472	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	4.8	409
473	Immunoregulation in Fungal Diseases. Microorganisms, 2016, 4, 47.	3.6	14
474	Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques. PLoS Pathogens, 2016, 12, e1006135.	4.7	24
475	Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 2016, 26, 202-204.	1.2	92
476	An Evaluation of the Impact of PDâ€1 Pathway Blockade on Reproductive Safety of Therapeutic PDâ€1 Inhibitors. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2016, 107, 108-119.	1.4	65
477	Chimeric Antigen Receptor (<scp>CAR</scp>) therapy for multiple myeloma. British Journal of Haematology, 2016, 172, 685-698.	2.5	53
478	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open, 2016, 1, e000122.	4.5	55
479	A mechanism for evasion of CTL immunity by altered O -glycosylation of HLA class I. Journal of Biochemistry, 2017, 161, mvw096.	1.7	11
480	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
481	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduction and Targeted Therapy, 2016, 1, 16025.	17.1	35
482	A20 Curtails Primary but Augments Secondary CD8+ T Cell Responses in Intracellular Bacterial Infection. Scientific Reports, 2016, 6, 39796.	3.3	20

#	Article	IF	Citations
483	The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Scientific Reports, 2016, 6, 27683.	3.3	69
484	Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. American Journal of Dermatopathology, 2016, 38, e159-e162.	0.6	7
485	Inhibitory immunologicznych punktÃ³w kontrolnych podziaÅ‚u komÃ³rki w leczeniu chorÃ³b nowotworowych. Acta Haematologica Polonica, 2016, 47, 155-162.	0.3	1
486	Malignant melanomaâ€"The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology, 2016, 106, 25-54.	4.4	33
487	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity, 2016, 44, 955-972.	14.3	462
488	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	2.2	107
489	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. OncoImmunology, 2016, 5, e1075114.	4.6	47
490	Leprosy as a model to understand cancer immunosurveillance and T cell anergy. Journal of Leukocyte Biology, 2016, 100, 47-54.	3.3	7
491	Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure, 2016, 24, 1719-1728.	3.3	86
492	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. Asian Journal of Urology, 2016, 3, 195-202.	1.2	12
493	Tumor-infiltrating Tim-3⁺ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. OncoImmunology, 2016, 5, e1200778.	4.6	47
494	Immunotherapy for malignant mesothelioma: reality check. Expert Review of Anticancer Therapy, 2016, 16, 1167-1176.	2.4	10
495	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. OncoImmunology, 2016, 5, e1235107.	4.6	104
496	Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway. Nature, 2016, 539, 102-106.	27.8	257
497	TGFÎ²1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discovery, 2016, 6, 1366-1381.	9.4	196
498	Programmed Death-Ligand 1 Expression and Response to the Antiâ€"Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109.	1.6	528
499	Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. Cancer Research, 2016, 76, 3756-3766.	0.9	31
500	Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ. Journal of Immunology, 2016, 197, 2509-2521.	0.8	25

#	Article	IF	Citations
501	Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?. Nature Reviews Rheumatology, 2016, 12, 593-604.	8.0	81
502	CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. Journal of Hematology and Oncology, 2016, 9, 124.	17.0	20
503	Advances in immunotherapy for melanoma management. Human Vaccines and Immunotherapeutics, 2016, 12, 2501-2511.	3.3	15
504	The CD8 Tâ€cell response during tolerance induction in liver transplantation. Clinical and Translational Immunology, 2016, 5, e102.	3.8	15
505	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	12.4	1,844
506	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	11.0	44
507	Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2016, 50, 836-848.	2.2	11
508	Serum levels of soluble programmed deathâ€1 and programmed death ligandâ€1 in systemic sclerosis: Association with extent of skin sclerosis. Journal of Dermatology, 2016, 43, 954-957.	1.2	34
509	Immune checkpoint inhibitorâ€related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology, 2016, 85, 331-339.	2.4	177
510	Monocyte programmed death ligand-1 expression after 3â€“4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Critical Care, 2016, 20, 124.	5.8	118
511	High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. OncoImmunology, 2016, 5, e1128612.	4.6	21
512	Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Deathâ€“Ligand 1. Journal of Immunology, 2016, 196, 1617-1625.	0.8	16
513	Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy, 2016, 16, 433-441.	3.1	16
514	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology, 2016, 47, 52-63.	2.0	284
515	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist, 2016, 21, 233-243.	3.7	71
516	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. OncoImmunology, 2016, 5, e1160184.	4.6	13
517	Basics of PD-1 in self-tolerance, infection, and cancer immunity. International Journal of Clinical Oncology, 2016, 21, 448-455.	2.2	74
518	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. Immunity, 2016, 44, 274-286.	14.3	144

#	Article	IF	Citations
519	Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Human Vaccines and Immunotherapeutics, 2016, 12, 1418-1429.	3.3	70
520	Immunotherapy of Cancer. , 2016, , .		3
521	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
522	Immune checkpoint pathways: perspectives on myeloid malignancies. Leukemia and Lymphoma, 2016, 57, 995-1001.	1.3	4
523	Targeting Oral Cancer. , 2016, , .		0
524	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 171-181.	1.6	38
525	Genetic and Epigenetic Regulation of PD-1 Expression. Journal of Immunology, 2016, 196, 2431-2437.	0.8	181
526	Immunotherapy in Head and Neck Cancers. , 2016, , 211-224.		0
527	Usp9X Is Required for Lymphocyte Activation and Homeostasis through Its Control of ZAP70 Ubiquitination and PKCÎ² Kinase Activity. Journal of Immunology, 2016, 196, 3438-3451.	0.8	35
528	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627
529	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	3.6	56
530	PD-1 Blunts the Function of Ovarian Tumorâ€“Infiltrating Dendritic Cells by Inactivating NF-ÎºB. Cancer Research, 2016, 76, 239-250.	0.9	84
531	Dysregulation of Antiviral Function of CD8⁺T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1â€“PD-L1 Axis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 642-651.	5.6	106
532	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Critical Reviews in Oncology/Hematology, 2016, 97, 65-71.	4.4	30
533	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma, 2016, 57, 563-571.	1.3	34
534	PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. Immunologic Research, 2016, 64, 412-423.	2.9	19
535	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: AÂphenotypic and functional characterization. Journal of Allergy and Clinical Immunology, 2017, 139, 335-346.e3.	2.9	379
536	PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients. Journal of Asthma, 2017, 54, 46-52.	1.7	6

#	Article	IF	Citations
537	Cancer immunotherapy â€" immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology, 2017, 13, 195-207.	9.6	515
538	Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells. Immunobiology, 2017, 222, 137-147.	1.9	35
539	A current perspective on cancer immune therapy: stepâ€byâ€step approach to constructing the magic bullet. Clinical and Translational Medicine, 2017, 6, 3.	4.0	58
540	Current Status and Prospective Regarding the Therapeutic Potential of Natural Autoantibodies in Cancer Therapy. Journal of Cellular Physiology, 2017, 232, 2649-2652.	4.1	15
541	Myeloidâ€derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunology and Cell Biology, 2017, 95, 538-548.	2.3	38
542	State of the art in anti-cancer mAbs. Journal of Biomedical Science, 2017, 24, 15.	7.0	64
543	Porphyromonas gingivalis activates NFÎºB and MAPK pathways in human oral epithelial cells. BMC Immunology, 2017, 18, 1.	2.2	71
544	PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology, Immunotherapy, 2017, 66, 551-564.	4.2	253
545	Characterization of the Antiâ€"PD-1 Antibody REGN2810 and Its Antitumor Activity in HumanPD-1Knock-In Mice. Molecular Cancer Therapeutics, 2017, 16, 861-870.	4.1	92
546	Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treatment Reviews, 2017, 54, 99-109.	7.7	27
547	Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies. Pathology, 2017, 49, 292-296.	0.6	6
548	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	1.4	156
549	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Molecular Imaging and Biology, 2017, 19, 903-914.	2.6	91
550	PSGL-1: A New Player in the Immune Checkpoint Landscape. Trends in Immunology, 2017, 38, 323-335.	6.8	96
551	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. Neurotherapeutics, 2017, 14, 1049-1065.	4.4	20
552	PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. Clinica Chimica Acta, 2017, 469, 191-194.	1.1	34
553	Genome-Edited T Cell Therapies. Current Stem Cell Reports, 2017, 3, 124-136.	1.6	13
554	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology, 2017, 28, 1388-1398.	1.2	70

#	Article	IF	Citations
555	PD-1 regulates KLRG1+ group 2 innate lymphoid cells. Journal of Experimental Medicine, 2017, 214, 1663-1678.	8.5	163
556	Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity. Cancer Research, 2017, 77, 3632-3643.	0.9	102
557	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (United States), 2017, 96, e6398.	1.0	43
558	Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. Journal of Immunology, 2017, 198, 205-217.	0.8	24
559	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Annals of the American Thoracic Society, 2017, 14, 1248-1260.	3.2	15
560	TCR + CD3 + CD4 â^' CD8 â^' effector T cells in psoriasis. Clinical Immunology, 2017, 181, 51-59.	3.2	39
561	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 2017, 545, 495-499.	27.8	1,489
562	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphomaâ€"New Therapeutic Targets. American Journal of Surgical Pathology, 2017, 41, 998-1004.	3.7	40
563	miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochemical and Biophysical Research Communications, 2017, 488, 425-431.	2.1	133
564	<scp>PD</scp>â€1 and <scp>PDâ€L1</scp> in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. Journal of Cutaneous Pathology, 2017, 44, 740-746.	1.3	32
565	Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients. Immunological Investigations, 2017, 46, 469-480.	2.0	10
566	Attenuation of Follicular Helper T Cellâ€"Dependent B Cell Hyperactivity by Abatacept Treatment in Primary SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2017, 69, 1850-1861.	5.6	134
567	Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Autoimmunity Reviews, 2017, 16, 767-773.	5.8	16
568	Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. British Journal of Pharmacology, 2017, 174, 3940-3955.	5.4	48
569	Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 2017, 24, 26.	7.0	501
570	A specific immune and lymphatic profile characterizes the pre-metastatic state of the sentinel lymph node in patients with early cervical cancer. OncoImmunology, 2017, 6, e1265718.	4.6	28
571	Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. Human Gene Therapy, 2017, 28, 493-509.	2.7	17
572	Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurgery, 2017, 102, 494-506.	1.3	29

#	Article	IF	Citations
573	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. Drug Resistance Updates, 2017, 33-35, 23-35.	14.4	16
574	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Research, 2017, 77, 6667-6678.	0.9	126
575	Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behavior. Nature Immunology, 2017, 18, 1342-1352.	14.5	83
576	Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Scientific Reports, 2017, 7, 7848.	3.3	43
577	Role of PD-1 in Immunity and Diseases. Current Topics in Microbiology and Immunology, 2017, 410, 75-97.	1.1	136
578	Differential regulation of PDâ€1 and its ligands in allergic asthma. Clinical and Experimental Allergy, 2017, 47, 1417-1425.	2.9	20
579	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. Clinical Skin Cancer, 2017, 2, 10-17.	0.1	1
580	ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. Journal of Experimental Medicine, 2017, 214, 2507-2521.	8.5	109
581	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. Cell Reports, 2017, 20, 1017-1028.	6.4	156
582	Macrophage-derived insulin-like growth factor-1 affects influenza vaccine efficacy through the regulation of immune cell homeostasis. Vaccine, 2017, 35, 4687-4694.	3.8	10
583	The Effect of Inhibitory Signals on the Priming of Drug Haptenâ€“Specific T Cells That Express Distinct Vβ2 Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.8	41
584	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Human Pathology, 2017, 66, 13-33.	2.0	46
585	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncoImmunology, 2017, 6, e1249561.	4.6	252
586	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist, 2017, 22, 81-88.	3.7	128
587	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Annals of Hematology, 2017, 96, 25-31.	1.8	81
588	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. Chinese Medical Journal, 2017, 130, 986-992.	2.3	15
589	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363.	2.0	35
590	Control of NK Cell Activation by Immune Checkpoint Molecules. International Journal of Molecular Sciences, 2017, 18, 2129.	4.1	64

#	Article	IF	Citations
591	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. International Journal of Molecular Sciences, 2017, 18, 1517.	4.1	69
592	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology, 2017, 8, 561.	3.5	1,276
593	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	4.8	225
594	Butyrophilins: an important new element of resistance. Central-European Journal of Immunology, 2017, 42, 399-403.	1.2	25
595	The Role of Dendritic Cell Maturation in the Induction of Insulin-Dependent Diabetes Mellitus. Frontiers in Immunology, 2017, 8, 327.	4.8	82
596	Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Frontiers in Immunology, 2017, 8, 641.	4.8	25
597	The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers, 2017, 9, 29.	3.7	31
598	Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. International Journal of Nanomedicine, 2017, Volume 12, 8337-8351.	6.7	19
599	Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. PLoS ONE, 2017, 12, e0178479.	2.5	112
600	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Systems Biology, 2017, 11, 70.	3.0	37
601	Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 839-845.	1.6	11
602	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
603	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. International Journal of Molecular Sciences, 2017, 18, 1331.	4.1	60
604	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. Vaccines, 2017, 5, 38.	4.4	14
605	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	1.8	115
606	PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8, 2171-2186.	1.8	234
607	Tumor-associated macrophagesâ€"additional effectors at anti-PD-1/PD-L1 therapy?. Journal of Thoracic Disease, 2017, 9, 4197-4200.	1.4	5
608	Targeting Melanoma with Cancer-Killing Viruses. The Open Virology Journal, 2017, 11, 28-47.	1.8	8

#	Article	IF	Citations
609	High-affinity human PD-L1 variants attenuate the suppression of T cell activation. Oncotarget, 2017, 8, 88360-88375.	1.8	30
610	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Translational Research, 2018, 196, 62-70.	5.0	9
611	PD-1 is required to maintain stem cell properties in human dental pulp stem cells. Cell Death and Differentiation, 2018, 25, 1350-1360.	11.2	31
612	Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. Cancer Immunology Research, 2018, 6, 378-388.	3.4	35
613	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940.	5.6	62
614	Arginaseâ€1 is neither constitutively expressed in nor required for myeloidâ€derived suppressor cellâ€mediated inhibition of Tâ€cell proliferation. European Journal of Immunology, 2018, 48, 1046-1058.	2.9	45
615	The Respiratory Environment Diverts the Development of Antiviral Memory CD8 T Cells. Journal of Immunology, 2018, 200, 3752-3761.	0.8	5
616	The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Clinica Chimica Acta, 2018, 482, 101-107.	1.1	38
617	Antigenâ€specific Helios^{â^'}, Neuropilinâ€1^{â^'} Tregs induce apoptosis of autoreactive B cells via <scp>PD</scp>â€L1. Immunology and Cell Biology, 2018, 96, 852-862.	2.3	12
618	Poor prognosis in Epsteinâ€“Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer, 2018, 21, 925-935.	5.3	13
619	Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Veterinary Immunology and Immunopathology, 2018, 198, 19-25.	1.2	31
620	Urine biomarkers informative of human kidney allograft rejection and tolerance. Human Immunology, 2018, 79, 343-355.	2.4	26
621	PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Scientific Reports, 2018, 8, 1605.	3.3	41
622	Clinical Development of PD-1 in Advanced Melanoma. Cancer Journal (Sudbury, Mass), 2018, 24, 7-14.	2.0	37
623	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 2018, 48, 91-106.e6.	14.3	95
625	Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Investigational New Drugs, 2018, 36, 509-512.	2.6	24
626	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. OncoImmunology, 2018, 7, e1413519.	4.6	21
627	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clinical and Experimental Medicine, 2018, 18, 165-175.	3.6	41

#	Article	IF	Citations
628	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E468-E477.	7.1	72
629	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Reports in Oncology, 2018, 10, 897-909.	0.7	57
630	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
631	Antibody-based delivery of tumor necrosis factor (L19-TNFÎ±) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model. Journal of Cancer Research and Clinical Oncology, 2018, 144, 499-507.	2.5	16
632	Monocyte Programmed Death Ligand-1, A Predicator for 28-Day Mortality in Septic Patients. American Journal of the Medical Sciences, 2018, 355, 362-367.	1.1	14
633	Tumour-immune dynamics with an immune checkpoint inhibitor. Letters in Biomathematics, 2018, 5, S137-S159.	0.1	17
634	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	14.3	1,437
635	The emerging role of immunotherapy in advanced urothelial cancers. Current Opinion in Oncology, 2018, 30, 172-180.	2.4	23
636	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs. Cellular and Molecular Immunology, 2018, 15, 377-387.	10.5	33
637	PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86.	2.4	100
638	Combination therapy strategies for improving PDâ€1 blockade efficacy: a new era in cancer immunotherapy. Journal of Internal Medicine, 2018, 283, 110-120.	6.0	162
639	Immune checkpoint inhibitors in cancer therapy: a focus on Tâ€regulatory cells. Immunology and Cell Biology, 2018, 96, 21-33.	2.3	225
640	Frequent PD-L1 Expression in Malignant Melanomas of the Vulva. International Journal of Gynecological Pathology, 2018, 37, 477-481.	1.4	10
641	The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167.	22.7	1,210
642	Establishment of the Method for Screening Small Molecule Inhibitors Blocking the Interaction Between PD-1 and Its Ligand PD-L1. Lecture Notes in Electrical Engineering, 2018, , 695-703.	0.4	1
643	PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Human Pathology, 2018, 72, 28-34.	2.0	44
644	Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents, 2018, 28, 69-80.	5.0	5
645	Mechanisms of Tumor Cellâ€“Intrinsic Immune Evasion. Annual Review of Cancer Biology, 2018, 2, 213-228.	4.5	65

#	Article	IF	Citations
646	Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Haematologica, 2018, 103, e126-e129.	3.5	28
647	Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e469-e476.	1.9	16
648	Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 2018, 191, 133-148.	2.6	57
649	Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. Surgery, 2018, 163, 130-136.	1.9	32
650	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight, 2018, 3, .	5.0	49
651	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	3.0	30
652	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Translational Lung Cancer Research, 2018, 7, 691-702.	2.8	8
655	The Contribution of Co-signaling Pathways to Anti-malarial T Cell Immunity. Frontiers in Immunology, 2018, 9, 2926.	4.8	7
656	A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab. BMJ Case Reports, 2018, 2018, bcr-2018-224608.	0.5	14
657	CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. Oncotarget, 2018, 9, 5208-5215.	1.8	73
658	The Role of Co-Stimulatory Molecules in Chagas Disease. Cells, 2018, 7, 200.	4.1	6
659	Analysis of PD-1 related immune transcriptional profile in different cancer types. Cancer Cell International, 2018, 18, 218.	4.1	15
660	CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation. Frontiers in Immunology, 2018, 9, 2994.	4.8	30
661	The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. Mediators of Inflammation, 2018, 2018, 1-12.	3.0	23
662	Progress of immune checkpoint therapy in the clinic (Review). Oncology Reports, 2019, 41, 3-14.	2.6	24
663	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
664	Immunogenetics of glioblastoma: the future of personalized patient management. Npj Precision Oncology, 2018, 2, 27.	5.4	23
665	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	1.8	6

#	Article	IF	Citations
666	The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45.	9.9	67
667	Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis. BioMed Research International, 2018, 2018, 1-8.	1.9	7
668	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biology and Medicine, 2018, 15, 116.	3.0	52
669	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. Frontiers in Immunology, 2018, 9, 2374.	4.8	150
670	Immunotherapy of alveolar echinococcosis via <scp>PD</scp>â€1/<scp>PD</scp>â€L1 immune checkpoint blockade in mice. Parasite Immunology, 2018, 40, e12596.	1.5	42
671	The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cellular Immunology, 2018, 334, 87-98.	3.0	15
672	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature Communications, 2018, 9, 4297.	12.8	101
673	Antigen in theÂAbsence of DAMPs Promotes Immune Tolerance: The Role of Dendritic Cells and Regulatory T Cells. , 2018, , 791-827.		1
674	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	4.8	127
675	The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirusâ€“Associated Head and Neck Squamous Cell Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 719-720.	2.5	1
676	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. Clinical and Experimental Medicine, 2018, 18, 487-494.	3.6	15
677	B7-H1 Expression Is Required for Human Endometrial Regenerative Cells in the Prevention of Transplant Vasculopathy in Mice. Stem Cells International, 2018, 2018, 1-12.	2.5	11
678	PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncology Reports, 2018, 40, 331-338.	2.6	6
679	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-20.	1.9	13
680	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. OncoTargets and Therapy, 2018, Volume 11, 4051-4064.	2.0	15
681	Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. Current Neurology and Neuroscience Reports, 2018, 18, 63.	4.2	88
682	Incomplete Memories: The Natural Suppression of Tissue-Resident Memory CD8 T Cells in the Lung. Frontiers in Immunology, 2018, 9, 17.	4.8	18
683	Programmed Cell Death Protein 1â€“PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection. Frontiers in Immunology, 2018, 9, 997.	4.8	19

#	Article	IF	Citations
684	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology, 2018, 8, 86.	2.8	926
685	Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. International Journal of Molecular Sciences, 2018, 19, 2000.	4.1	33
686	CD8+ T cells with high TGFâ€Î²1 expression cause lymph node fibrosis following HIV infection. Molecular Medicine Reports, 2018, 18, 77-86.	2.4	7
687	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698.	6.1	39
688	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
689	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	1.9	10
690	Antigen-Specific Signal Transduction. , 2018, , 282-305.		1
691	Two Vaccines forStaphylococcus aureusInduce a B-Cell-Mediated Immune Response. MSphere, 2018, 3, .	2.9	16
692	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086.	9.4	2,128
693	Soluble B7-H3 (sB7-H3) is over-expressed in the serum of type 1 diabetes patients. Diabetes Research and Clinical Practice, 2018, 143, 332-336.	2.8	6
694	Preliminary application of 125Iâ€“nivolumab to detect PD-1 expression in colon cancer via SPECT. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318, 1237-1242.	1.5	7
696	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
697	Comparison of the Percentage of Regulatory T cells and their p-STAT5 Expression in Allergic and Non-Allergic Common Variable Immunodeficiency Patients. Immunological Investigations, 2019, 48, 52-63.	2.0	12
698	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 52, 144-160.	2.6	10
699	Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs, 2019, 11, 1443-1451.	5.2	97
700	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-ÎºB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. Cell Communication and Signaling, 2019, 17, 89.	6.5	19
701	PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease. Scientific Reports, 2019, 9, 11638.	3.3	1
702	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. Metabolic Brain Disease, 2019, 34, 1705-1712.	2.9	8

#	Article	IF	Citations
703	A Thpok-Directed Transcriptional Circuitry Promotes Bcl6 and Maf Expression to Orchestrate T Follicular Helper Differentiation. Immunity, 2019, 51, 465-478.e6.	14.3	30
704	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. Physiological Reviews, 2019, 99, 1765-1817.	28.8	550
705	Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases. Clinical Microbiology Reviews, 2019, 32, .	13.6	74
706	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. Journal of Immunology, 2019, 203, 844-852.	0.8	15
707	PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions. Journal of Autoimmunity, 2019, 105, 102296.	6.5	12
708	AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report. Case Reports in Oncology, 2019, 12, 456-465.	0.7	18
709	Divergent Effects of a Transient Corticosteroid Therapy on Virus-Specific Quiescent and Effector CD8+ T Cells. Frontiers in Immunology, 2019, 10, 1521.	4.8	14
710	Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: a mini review. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 507-512.	0.5	31
711	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. Frontiers in Cellular and Infection Microbiology, 2019, 9, 207.	3.9	194
712	Induction of Follicular-Like CXCR5⁺CD8⁺T Cells by TGF-Î²1/IL-23 Is Limited During HIV Infection. Viral Immunology, 2019, 32, 278-288.	1.3	11
713	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554.	3.7	73
714	CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers. Biochemistry and Biophysics Reports, 2019, 20, 100690.	1.3	18
715	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. Cells, 2019, 8, 1213.	4.1	14
716	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Seminars in Immunology, 2019, 42, 101295.	5.6	16
717	Immune regulation and cytotoxic T cell activation of IL-10 agonists â€“ Preclinical and clinical experience. Seminars in Immunology, 2019, 44, 101325.	5.6	30
718	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	2.5	32
719	PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. Molecular Pharmaceutics, 2019, 16, 4940-4953.	4.6	29
720	Pembrolizumab in lung cancer: current evidenceÂand future perspectives. Future Oncology, 2019, 15, 3327-3336.	2.4	4

#	Article	IF	Citations
721	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. Russian Journal of Bioorganic Chemistry, 2019, 45, 225-240.	1.0	6
722	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology, 2019, 10, 2298.	4.8	244
723	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. Journal of Clinical Medicine, 2019, 8, 1547.	2.4	30
724	Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. Tumor Biology, 2019, 41, 101042831987374.	1.8	3
725	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. Molecular Aspects of Medicine, 2019, 70, 117-126.	6.4	41
726	Antibody-mediated targeting of TNFR2 activates CD8 ⁺ T cells in mice and promotes antitumor immunity. Science Translational Medicine, 2019, 11, .	12.4	39
727	InÂVivo Imaging of GVHD and GVL. , 2019, , 51-68.		2
728	Programmed cell death protein receptor and ligands in haematological malignancies â€“ Current status. Critical Reviews in Oncology/Hematology, 2019, 135, 47-58.	4.4	4
729	The Prognostic and Therapeutic Value of PD-L1 in Glioma. Frontiers in Pharmacology, 2018, 9, 1503.	3.5	85
730	Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia. International Journal of Molecular Sciences, 2019, 20, 583.	4.1	16
731	Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 482.	4.1	4
732	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	4.4	76
733	Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. International Journal of Molecular Sciences, 2019, 20, 2836.	4.1	23
734	Development of the Inhibitors That Target the PD-1/PD-L1 Interactionâ€"A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Molecules, 2019, 24, 2071.	3.8	106
735	Advances in Immunotherapy and Periocular Malignancy. Seminars in Ophthalmology, 2019, 34, 327-333.	1.6	9
736	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	8.5	125
737	Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research, 2019, 143, 1-62.	5.0	28
738	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. Cancer Letters, 2019, 457, 74-85.	7.2	15

#	Article	IF	Citations
739	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. Cancer Immunology Research, 2019, 7, 963-976.	3.4	36
740	The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology, 2019, 10, 204062071984159.	2.5	23
741	Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study. Journal of Ovarian Research, 2019, 12, 37.	3.0	31
742	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. MAbs, 2019, 11, 666-680.	5.2	25
743	Low levels of SIV-specific CD8+ T cells in germinal centers characterizes acute SIV infection. PLoS Pathogens, 2019, 15, e1007311.	4.7	18
744	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia and Lymphoma, 2019, 60, 2498-2507.	1.3	21
745	Differential expression of programmed deathâ€1 according to the histological differentiation of cutaneous squamous cell carcinoma. British Journal of Dermatology, 2019, 181, 628-629.	1.5	2
746	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450.	3.4	32
747	Depletion of PD-1-positive cells ameliorates autoimmune disease. Nature Biomedical Engineering, 2019, 3, 292-305.	22.5	48
748	Molecular cloning, expression and characterization of Pekin duck programmed death-1. Gene, 2019, 702, 182-193.	2.2	0
749	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PDâ€1 receptor. International Journal of Cancer, 2019, 145, 1660-1668.	5.1	65
750	B cell checkpoints in autoimmune rheumatic diseases. Nature Reviews Rheumatology, 2019, 15, 303-315.	8.0	62
751	The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides. Journal of Neuroimmunology, 2019, 332, 78-90.	2.3	23
752	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	7.6	43
753	FcÎ³R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 292.	4.8	111
754	Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2019, 8, 236.	2.4	49
755	PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Letters, 2019, 450, 1-13.	7.2	126
756	The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy and Childbirth, 2019, 19, 74.	2.4	58

#	Article	IF	Citations
757	Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta Biomaterialia, 2019, 88, 15-31.	8.3	127
758	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. Expert Opinion on Biological Therapy, 2019, 19, 457-467.	3.1	7
759	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances, 2019, 3, 2550-2561.	5.2	44
760	Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method. Scientific Reports, 2019, 9, 16727.	3.3	43
761	The CCâ€² loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation. Scientific Reports, 2019, 9, 19191.	3.3	15
762	Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2019, 20, 6337.	4.1	23
763	Blocking TGF-Î² Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor . OncoTargets and Therapy, 2019, Volume 12, 9527-9538.	2.0	93
764	Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports. Journal of Visualized Experiments, 2019, , .	0.3	0
765	Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4+ T Cells. Cell Reports, 2019, 29, 3019-3032.e6.	6.4	50
766	Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews, 2019, 38, 573-594.	5.9	20
767	Immunotherapy for Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030627.	6.2	41
768	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
769	Dendritic cells, T cells and their interaction in rheumatoid arthritis. Clinical and Experimental Immunology, 2019, 196, 12-27.	2.6	108
770	Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Reports, 2019, 26, 94-107.e7.	6.4	42
771	PDâ€1 expression is upregulated on adapted TÂcells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state. European Journal of Immunology, 2019, 49, 112-120.	2.9	3
772	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. International Immunopharmacology, 2019, 66, 127-138.	3.8	18
773	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research, 2019, 25, 1564-1573.	7.0	33
774	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.3	51

#	Article	IF	Citations
775	Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer, 2019, 18, 10.	19.2	810
776	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	17.0	113
777	The Emergence and Functional Fitness of Memory CD4+ T Cells Require the Transcription Factor Thpok. Immunity, 2019, 50, 91-105.e4.	14.3	94
778	Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo. Science and Technology Libraries, 2019, 38, 1-29.	1.8	0
779	An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression. PLoS ONE, 2019, 14, e0210540.	2.5	29
780	Oncostatic treatment effect of triple negative breast cancer cell line with copper (I)â€nicotinate complex. Journal of Cellular Biochemistry, 2019, 120, 4278-4290.	2.6	8
781	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 2019, 40, 17-65.	20.1	349
782	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
783	Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunology, 2019, 12, 21-35.	6.0	13
784	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. Journal of Medicinal Chemistry, 2019, 62, 1715-1730.	6.4	92
785	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Therapy, 2020, 27, 235-245.	4.6	42
786	Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomedicine and Pharmacotherapy, 2020, 121, 109570.	5.6	129
787	Effects of the programmed cell death 1 (PDCD1) polymorphisms in susceptibility to systemic lupus erythematosus. International Journal of Immunogenetics, 2020, 47, 57-64.	1.8	12
788	Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. Molecular Cancer Therapeutics, 2020, 19, 270-281.	4.1	11
789	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry, 2020, 186, 111876.	5.5	98
790	The Immunosuppressive Microenvironment in BRCA1-IRISâ€“Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages. Cancer Research, 2020, 80, 1102-1117.	0.9	57
791	Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Cancer Letters, 2020, 472, 8-18.	7.2	31
792	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathology and Oncology Research, 2020, 26, 651-663.	1.9	18

#	Article	IF	Citations
793	Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders. Journal of Clinical Medicine, 2020, 9, 9.	2.4	20
794	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
795	The Role of Innate Lymphoid Cells in the Regulation of Immune Homeostasis in Sepsis-Mediated Lung Inflammation. Diagnostics, 2020, 10, 808.	2.6	8
796	Colorectal Cancer Immunotherapy: Options and Strategies. Frontiers in Immunology, 2020, 11, 1624.	4.8	207
797	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Communications Biology, 2020, 3, 571.	4.4	31
798	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	4.5	24
799	Emerging Targets of Immunotherapy in Gynecologic Cancer . OncoTargets and Therapy, 2020, Volume 13, 11869-11882.	2.0	6
800	Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31319-31330.	7.1	29
801	Regulation of PD-L1 Expression by NF-Î¹B in Cancer. Frontiers in Immunology, 2020, 11, 584626.	4.8	179
802	Diacylglycerol kinase Î¶ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. , 2020, 8, e001521.		10
803	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. Seminars in Cancer Biology, 2022, 86, 1033-1057.	9.6	14
804	Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis. Frontiers in Immunology, 2020, 11, 574491.	4.8	13
805	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	3.7	205
806	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€"Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	4.8	60
807	An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell, 2020, 182, 1009-1026.e29.	28.9	194
808	An overview on precision therapy in bladder cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 347-361.	0.7	0
809	Novel Analgesics with Peripheral Targets. Neurotherapeutics, 2020, 17, 784-825.	4.4	11
810	KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28239-28250.	7.1	37

#	Article	IF	Citations
811	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Review of Clinical Pharmacology, 2020, 13, 1147-1158.	3.1	8
812	Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor. Journal of Dermatology, 2020, 47, e425-e426.	1.2	1
813	Cancer immunotherapy harnessing Î³Î´ T cells and programmed deathâ€1. Immunological Reviews, 2020, 298, 237-253.	6.0	16
814	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 576314.	2.8	17
815	Immune Checkpoints in Viral Infections. Viruses, 2020, 12, 1051.	3.3	33
816	Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. International Journal of Molecular Sciences, 2020, 21, 6772.	4.1	2
817	Quantitative and Functional Analysis of PD-1+ NK Cells in Patients With Autoimmune Thyroid Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4001-e4011.	3.6	5
818	Dysfunction of CD8â€‰+â€‰PD-1â€‰+â€‰T cells in type 2 diabetes caused by the impairment of metabolism-immune axis. Scientific Reports, 2020, 10, 14928.	3.3	28
819	T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells. Frontiers in Immunology, 2020, 11, 2025.	4.8	215
820	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers, 2020, 12, 2592.	3.7	8
821	Revisiting the PD-1 pathway. Science Advances, 2020, 6, .	10.3	277
822	LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1 . OncoTargets and Therapy, 2020, Volume 13, 8547-8556.	2.0	26
823	Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	4.3	80
824	Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Cancers, 2020, 12, 2274.	3.7	71
825	Hairy cell leukemia expresses programmed death-1. Blood Cancer Journal, 2020, 10, 115.	6.2	4
826	Accelerator or Brake: Immune Regulators in Malaria. Frontiers in Cellular and Infection Microbiology, 2020, 10, 610121.	3.9	5
827	Presence of tumor-infiltrating CD8 ⁺ T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis. OncoImmunology, 2020, 9, 1854519.	4.6	15
828	Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. Frontiers in Medicine, 2020, 7, 584382.	2.6	3

#	Article	IF	Citations
829	PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8089.	4.1	25
830	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. Journal of Clinical Medicine, 2020, 9, 3529.	2.4	10
831	Cardiotoxicity danger in immunotherapy. IUBMB Life, 2020, 72, 1160-1167.	3.4	4
832	How microRNAs affect the PD-L1 and its synthetic pathway in cancer. International Immunopharmacology, 2020, 84, 106594.	3.8	19
833	The Synthesis and Antiâ€tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEEâ˜G) Scaffolds with Multiple PDâ€1 Peptides Attached. ChemMedChem, 2020, 15, 1128-1138.	3.2	4
834	Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 1075.	4.8	36
835	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
836	The roles of programmed death ligand 1 in virus-associated cancers. Infection, Genetics and Evolution, 2020, 84, 104368.	2.3	16
837	Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function. Journal of Infectious Diseases, 2020, 222, 1540-1549.	4.0	7
838	Human cancer germline antigen-specific cytotoxic T cellâ€"what can we learn from patient. Cellular and Molecular Immunology, 2020, 17, 684-692.	10.5	12
839	Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression. Gene, 2020, 754, 144888.	2.2	24
840	Regulation of PD-1 in T cells for cancer immunotherapy. European Journal of Pharmacology, 2020, 881, 173240.	3.5	27
841	PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells, 2020, 9, 1376.	4.1	31
842	Relationship between T cells and microbiota in health and disease. Progress in Molecular Biology and Translational Science, 2020, 171, 95-129.	1.7	4
843	A New Hope. Current Oncology, 2020, 27, 41-42.	2.2	0
844	Noncoding RNAs: the shot callers in tumor immune escape. Signal Transduction and Targeted Therapy, 2020, 5, 102.	17.1	37
845	The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer. Medicine (United States), 2020, 99, e19367.	1.0	4
846	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	1.6	7

#	Article	IF	Citations
847	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. Frontiers in Medicine, 2020, 7, 50.	2.6	11
848	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. Future Oncology, 2020, 16, 497-506.	2.4	16
849	Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis. Carcinogenesis, 2020, 41, 1518-1528.	2.8	23
850	The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?. Frontiers in Immunology, 2020, 11, 1223.	4.8	18
851	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	10.5	1,136
852	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	9.6	35
853	Role of microRNA 4717, its effects on programmed cell death protein-1 in hepatitis B infection, and interaction between PDCD1 and miR-4717. European Journal of Inflammation, 2020, 18, 205873922093460.	0.5	0
854	Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells. Life Sciences, 2020, 256, 118005.	4.3	32
855	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. Journal of Clinical Oncology, 2020, 38, 1138-1145.	1.6	32
856	Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor. Science China Mathematics, 2020, 63, 465-484.	1.7	10
857	PDâ€1 and PDâ€L1 expression on Tâ€cell subsets in women with unexplained recurrent pregnancy losses. American Journal of Reproductive Immunology, 2020, 83, e13230.	1.2	23
858	HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs, 2020, 12, 1724751.	5.2	25
859	CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research, 2020, 26, 1953-1964.	7.0	35
860	Functional tumor specific CD8Â+ÂT cells in spleen express a high level of PD-1. International Immunopharmacology, 2020, 80, 106242.	3.8	8
861	Immune checkpoint molecules in pregnancy: Focus on regulatory TÂcells. European Journal of Immunology, 2020, 50, 160-169.	2.9	53
862	Loading of Primary Human T Lymphocytes with Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Does Not Impair Their Activation after Polyclonal Stimulation. Cells, 2020, 9, 342.	4.1	14
863	Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model. ACS Omega, 2020, 5, 8474-8482.	3.5	10
864	CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio, 2020, 10, 1162-1170.	2.3	3

#	Article	IF	Citations
865	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. Science China Life Sciences, 2020, 63, 1499-1514.	4.9	20
866	Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nature Communications, 2020, 11, 1806.	12.8	62
867	The PD-1/PD-L pathway in rheumatic diseases. Journal of the Formosan Medical Association, 2021, 120, 48-59.	1.7	26
868	Characteristic pathological features of keratinocyte death in a case of Stevensâ€“Johnson syndrome manifested by an immune checkpoint inhibitor. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e142-e145.	2.4	8
869	Inhibition of programmed deathâ€1 decreases neointimal hyperplasia after patch angioplasty. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2021, 109, 269-278.	3.4	20
870	The Stone Guest: How Does pH Affect Binding Properties of PDâ€1/PDâ€L1 Inhibitors?. ChemMedChem, 2021, 16, 568-577.	3.2	9
871	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54.	9.5	31
872	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research, 2021, 9, 156-169.	3.4	56
873	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	4.4	26
874	Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer, 2021, 29, 2029-2035.	2.2	7
875	A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer, 2021, 12, 2735-2746.	2.5	105
876	Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. Frontiers in Immunology, 2020, 11, 584937.	4.8	4
877	Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis. International Journal of Biological Sciences, 2021, 17, 1263-1276.	6.4	11
878	Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. Journal of Translational Autoimmunity, 2021, 4, 100126.	4.0	2
879	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research, 2021, 81, 3079-3091.	0.9	27
880	T-cell-intrinsic and -extrinsic regulation of PD-1 function. International Immunology, 2021, 33, 693-698.	4.0	8
881	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
882	Genetic and molecular biology of systemic lupus erythematosus among Iranian patients: an overview. Autoimmunity Highlights, 2021, 12, 2.	3.9	5

#	Article	IF	Citations
883	The PD-1:PD-L1 axis in Inflammatory Arthritis. BMC Rheumatology, 2021, 5, 1.	1.6	29
884	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698.		78
885	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 619650.	2.4	17
886	Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets. ACS Nano, 2021, 15, 3441-3452.	14.6	42
887	History and emerging trends in chemotherapy for gastric cancer. Annals of Gastroenterological Surgery, 2021, 5, 446-456.	2.4	25
888	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	9.6	21
889	Epigenetic regulation of T cell adaptive immunity. Immunological Reviews, 2021, 300, 9-21.	6.0	16
890	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 561083.	4.8	12
891	Biomechanics of T Cell Dysfunctions in Chronic Diseases. Frontiers in Immunology, 2021, 12, 600829.	4.8	11
892	Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduction and Targeted Therapy, 2021, 6, 62.	17.1	198
893	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 549777.	2.8	26
894	Combined antiâ€PDâ€1 and antiâ€CTLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 2021, 51, 544-556.	2.9	71
895	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458.	1.9	15
896	Modeling the tumor immune microenvironment for drug discovery using 3D culture. APL Bioengineering, 2021, 5, 010903.	6.2	14
897	An in vivo method for diversifying the functions of therapeutic antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	3
898	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. Pharmaceuticals, 2021, 14, 288.	3.8	21
899	Host Components That Modulate the Disease Caused by hMPV. Viruses, 2021, 13, 519.	3.3	9
900	Heat-Inactivation of Human Serum Destroys C1 Inhibitor, Pro-motes Immune Complex Formation, and Improves Human T Cell Function. International Journal of Molecular Sciences, 2021, 22, 2646.	4.1	11

#	Article	IF	Citations
901	The Role of CD276 in Cancers. Frontiers in Oncology, 2021, 11, 654684.	2.8	59
902	Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies. Scandinavian Journal of Gastroenterology, 2021, 56, 671-679.	1.5	7
903	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers, 2021, 13, 1370.	3.7	9
904	PD-1 Is an Immune-Inflammatory Potential Biomarker in Cerebrospinal Fluid and Serum of Intractable Epilepsy. BioMed Research International, 2021, 2021, 1-10.	1.9	9
905	PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling. International Journal of Oral Science, 2021, 13, 8.	8.6	15
906	High Levels of Thyroid Hormone Impair Regulatory T Cell Function Via Reduced PD-1 Expression. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2738-2753.	3.6	8
907	Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. Bioorganic and Medicinal Chemistry, 2021, 33, 116038.	3.0	11
908	Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia. Cancers, 2021, 13, 1536.	3.7	31
909	Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers, 2021, 13, 1209.	3.7	18
910	PDâ€L1 positively regulates MET phosphorylation through inhibiting PTP1B. Cancer Science, 2021, 112, 1878-1887.	3.9	6
911	Increased PDâ€L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation. Photochemistry and Photobiology, 2021, 97, 778-784.	2.5	9
912	The Outcome of Neutrophil-T Cell Contact Differs Depending on Activation Status of Both Cell Types. Frontiers in Immunology, 2021, 12, 633486.	4.8	23
913	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 645699.	4.8	18
914	Anti-angiogenic agents â€" overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nature Reviews Clinical Oncology, 2021, 18, 527-540.	27.6	162
915	Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression. Scientific Reports, 2021, 11, 7772.	3.3	5
916	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. Seminars in Cancer Biology, 2022, 85, 246-252.	9.6	38
917	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. Neuroscience Bulletin, 2021, 37, 1188-1202.	2.9	30
918	Metabolic barriers to cancer immunotherapy. Nature Reviews Immunology, 2021, 21, 785-797.	22.7	245

#	Article	IF	Citations
919	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 920-937.	4.4	18
920	A review of signaling and transcriptional control in T follicular helper cell differentiation. Journal of Leukocyte Biology, 2021, , .	3.3	8
921	Enhanced generation of influenza-specific tissue resident memory CD8 T cells in NK-depleted mice. Scientific Reports, 2021, 11, 8969.	3.3	2
922	Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center. Journal of Dermatology, 2021, 48, 979-988.	1.2	2
923	A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?. Medicinal Chemistry Research, 2021, 30, 1230-1239.	2.4	1
924	PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells, 2021, 10, 1152.	4.1	12
925	PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment. Communications Biology, 2021, 4, 581.	4.4	14
926	Immune Checkpoints as a Novel Source for Diagnostic and Therapeutic Target in Celiac Disease. , 0, , .		0
927	Modulating T Follicular Cells In Vivo Enhances Antigen-Specific Humoral Immunity. Journal of Immunology, 2021, 206, 2583-2595.	0.8	0
928	Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Journal of Medicinal Chemistry, 2021, 64, 7390-7403.	6.4	43
929	Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. International Journal of Molecular Sciences, 2021, 22, 5383.	4.1	10
930	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	4.4	20
931	The influence of monoclonal antibodies for cancer treatment on the endocrine system. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 317-327.	0.1	0
932	The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Seminars in Cancer Biology, 2022, 86, 1045-1055.	9.6	17
933	Hookworm treatment induces a decrease of suppressive regulatory T cell associated with a Th2 inflammatory response. PLoS ONE, 2021, 16, e0252921.	2.5	3
934	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opinion on Biological Therapy, 2021, 21, 1575-1590.	3.1	7
935	Amlexanox enhances the antitumor effect of anti-PD-1 antibody. Biochemical and Biophysical Research Communications, 2021, 560, 1-6.	2.1	4
936	The importance of sPD-1, sOX40L and sGITR in terms of clinicopathology and histopathology in gastric cancer. Turkish Journal of Biochemistry, 2021, .	0.5	1

#	Article	IF	Citations
937	The PDâ€1 Interactome. Advanced Biology, 2021, 5, e2100758.	2.5	21
938	Programmed Cell Death-1 Pathway Deficiency Enhances Autoimmunity Leading to Dacryoadenitis of Mice. American Journal of Pathology, 2021, 191, 1077-1093.	3.8	6
939	If small molecules immunotherapy comes, can the prime be far behind?. European Journal of Medicinal Chemistry, 2021, 218, 113356.	5.5	23
940	The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. Current Problems in Cancer, 2021, 45, 100760.	2.0	14
941	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	2.8	16
942	Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8+ T Cells in a Tissue-Dependent Manner and Can Inhibit T Cell Responses to Stimulation. Frontiers in Immunology, 2021, 12, 704862.	4.8	7
943	Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets. Virus Research, 2021, 299, 198347.	2.2	3
944	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, 13, 3676.	3.7	13
945	Tryptophan potentiates CD8⁺T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. , 2021, 9, e002840.		24
946	Early Transcriptional Liver Signatures in Experimental Visceral Leishmaniasis. International Journal of Molecular Sciences, 2021, 22, 7161.	4.1	4
947	Tâ€Cellâ€Derived Nanovesicles for Cancer Immunotherapy. Advanced Materials, 2021, 33, e2101110.	21.0	41
949	Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimerâ€Based Hybrid Nanocomplex. Advanced Healthcare Materials, 2021, 10, e2100833.	7.6	31
950	Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis. PLoS ONE, 2021, 16, e0255574.	2.5	1
951	Activated Î³Î´ T Cells With Higher CD107a Expression and Inflammatory Potential During Early Pregnancy in Patients With Recurrent Spontaneous Abortion. Frontiers in Immunology, 2021, 12, 724662.	4.8	12
952	Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Therapy, 2022, 29, 814-824.	4.6	12
953	Immuneâ€related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell carcinoma with stasis dermatitis. IJU Case Reports, 2021, 4, 386-390.	0.3	0
954	Tumor Microenvironment in Breast Cancerâ€”Updates on Therapeutic Implications and Pathologic Assessment. Cancers, 2021, 13, 4233.	3.7	72
955	T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis. Diagnostic Pathology, 2021, 16, 84.	2.0	7

#	Article	IF	Citations
956	A structural perspective on the design of decoy immune modulators. Pharmacological Research, 2021, 170, 105735.	7.1	0
957	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in Pharmacology, 2021, 12, 731798.	3.5	134
958	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. Journal of Personalized Medicine, 2021, 11, 971.	2.5	5
959	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 539-557.	1.8	4
960	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037895.	6.2	24
961	The human liver microenvironment shapes the homing and function of CD4⁺T-cell populations. Gut, 2022, 71, 1399-1411.	12.1	19
962	Role of the PDâ€1/PDâ€L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Molecular Neurobiology, 2021, 58, 6249-6271.	4.0	15
963	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers, 2021, 13, 4923.	3.7	19
964	Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2021, 21, 1147-1164.	3.1	17
965	Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. Cancers, 2021, 13, 4616.	3.7	13
966	Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?. Cells, 2021, 10, 2333.	4.1	13
967	Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	3
968	Immune checkpoint programmed death-1 mediates abdominal aortic aneurysm and pseudoaneurysm progression. Biomedicine and Pharmacotherapy, 2021, 142, 111955.	5.6	9
969	Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. , 2021, 227, 107870.		13
970	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
971	Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.		2
972	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. OncoImmunology, 2021, 10, 1938381.	4.6	10
973	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2020, 11, 622442.	4.8	39

#	Article	IF	Citations
974	Cancer Immunotherapy. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 1-41.	0.1	0
975	PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. OncoImmunology, 2021, 10, 1943180.	4.6	54
976	Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer. , 2020, , 67-157.		1
977	Pax-5/BSAP: Regulator of Specific Gene Expression and Differentiation in B Lymphocytes. Current Topics in Microbiology and Immunology, 2000, 245, 169-194.	1.1	27
978	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59.	1.6	232
979	Co-signal Molecules in T-Cell Activation. Advances in Experimental Medicine and Biology, 2019, 1189, 3-23.	1.6	45
980	Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors. Advances in Experimental Medicine and Biology, 2019, 1189, 85-133.	1.6	14
981	Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Critical Reviews in Oncology/Hematology, 2020, 151, 102965.	4.4	17
982	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
983	A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis. Shock, 2021, 55, 806-815.	2.1	15
984	Experimental exposure of Burkholderia pseudomallei crude culture filtrate upregulates PD-1 on T lymphocytes. Access Microbiology, 2020, 2, acmi000110.	0.5	1
988	The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes and Development, 2000, 14, 521-535.	5.9	337
989	B cells from African American lupus patients exhibit an activated phenotype. JCI Insight, 2016, 1, e87310.	5.0	37
990	Activation and inhibition of lymphocytes by costimulation. Journal of Clinical Investigation, 2002, 109, 295-299.	8.2	249
991	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61.	8.2	66
992	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. Journal of Clinical Investigation, 2020, 130, 3051-3068.	8.2	90
993	Activation and inhibition of lymphocytes by costimulation. Journal of Clinical Investigation, 2002, 109, 295-299.	8.2	140
994	Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. Journal of Clinical Investigation, 2014, 124, 2425-2440.	8.2	203

#	Article	IF	Citations
995	Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer. Medical Science Monitor, 2019, 25, 3495-3502.	1.1	3
996	Cloning and Characterization of Porcine 4Ig-B7-H3: A Potent Inhibitor of Porcine T-Cell Activation. PLoS ONE, 2011, 6, e21341.	2.5	6
997	Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia. PLoS ONE, 2012, 7, e35178.	2.5	68
998	Re-Evaluation of PD-1 Expression by T Cells as a Marker for Immune Exhaustion during SIV Infection. PLoS ONE, 2013, 8, e60186.	2.5	65
999	Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations. PLoS ONE, 2013, 8, e78367.	2.5	19
1000	TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005490.	4.7	147
1001	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget, 2016, 7, 72961-72977.	1.8	258
1002	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 2016, 7, 76604-76612.	1.8	93
1003	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427.	1.8	70
1004	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 2017, 8, 21539-21553.	1.8	103
1005	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget, 2017, 8, 101994-102005.	1.8	72
1006	PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget, 2018, 9, 32024-32035.	1.8	25
1007	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget, 2016, 7, 10332-10344.	1.8	50
1008	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
1009	Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biology and Medicine, 2020, 17, 626-639.	3.0	7
1010	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. Annals of Translational Medicine, 2020, 8, 1478-1478.	1.7	17
1011	Immunological Synapse in the Biology of Chronic Lymphocytic Leukemia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 313-318.	0.4	2
1012	Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 2019, 26, 3009-3025.	2.4	286

#	Article	IF	Citations
1013	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Current Drug Targets, 2017, 18, 315-331.	2.1	39
1014	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 100-112.	1.6	16
1015	The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1+ to CD8+ Lymphocyte Ratio in Patients with Colorectal Cancer. Anticancer Research, 2017, 37, 4165-4172.	1.1	12
1016	PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma. Anticancer Research, 2018, 38, 2069-2078.	1.1	36
1017	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. Acta Haematologica Polonica, 2018, 49, 207-227.	0.3	5
1018	The role of B cells in animal models of rheumatoid arthritis. Frontiers in Bioscience - Landmark, 2007, 12, 1722.	3.0	19
1019	Experimental advances in understanding allergic airway inflammation. Frontiers in Bioscience - Scholar, 2013, S5, 167-180.	2.1	3
1020	Observational Molecular Case-Control Study of Genetic Polymorphisms 1 in Programmed Cell Death Protein-1 in Patients with Oral Lichen Planus. Asian Pacific Journal of Cancer Prevention, 2019, 20, 421-424.	1.2	3
1021	Identification and Characterization of The Promoter and Upstream Regulation Region of Mouse PD-1*. Progress in Biochemistry and Biophysics, 2010, 37, 527-533.	0.3	1
1022	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. World Journal of Gastroenterology, 2008, 14, 6853.	3.3	11
1023	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World Journal of Gastroenterology, 2009, 15, 5129.	3.3	18
1024	Specific CD8⁺T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World Journal of Gastroenterology, 2016, 22, 6469.	3.3	53
1025	Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimodâ€‘treated mice. International Journal of Molecular Medicine, 2020, 46, 869-879.	4.0	8
1026	Cancer stem cells and immunoresistance: clinical implications and solutions. Translational Lung Cancer Research, 2015, 4, 689-703.	2.8	91
1027	IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors. ImmunoHorizons, 2019, 3, 13-25.	1.8	66
1028	Lymphopenia-induced proliferation of CD4 T-cells is associated with CD4 T-lymphocyte exhaustion in treated HIV-infected patients. Indian Journal of Medical Research, 2018, 147, 376.	1.0	15
1029	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1167-1175.	0.9	51
1030	New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors. Advances in Bioscience and Biotechnology (Print), 2013, 04, 34-37.	0.7	1

#	Article	IF	Citations
1031	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 242.	1.0	12
1032	CD28/CTLA-4/B7 and CD40/CD40L costimulation and activation of regulatory T cells. World Journal of Immunology, 2014, 4, 63.	0.5	3
1033	Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy. ELife, 2014, 3, .	6.0	52
1034	Long-term antigen exposure irreversibly modifies metabolic requirements for T cell function. ELife, 2018, 7, .	6.0	31
1035	Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. Cancers, 2021, 13, 5225.	3.7	8
1036	Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Reports, 2021, 37, 109844.	6.4	120
1037	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	12.4	33
1038	Improving CAR T-Cell Persistence. International Journal of Molecular Sciences, 2021, 22, 10828.	4.1	44
1039	Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B, 2021, 11, 3727-3739.	12.0	34
1040	Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect. European Journal of Pharmaceutical Sciences, 2022, 168, 106044.	4.0	8
1041	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annual Review of Medicine, 2022, 73, 231-250.	12.2	11
1042	Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction. Cells, 2021, 10, 2645.	4.1	18
1043	Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Antiâ€“PD-1/PD-L1 Agents. Cancer Immunology Research, 2021, 9, 1451-1464.	3.4	15
1044	Costimulatory Molecules in T Cell Activation and Transplantation. , 2004, , 291-312.		0
1046	Co-stimulation Regulation of Immune Tolerance and Autoimmunity. , 2007, , 121-138.		0
1047	New Approaches for Optimizing Melanoma Vaccines. Translational Medicine Series, 2008, , 143-160.	0.0	1
1048	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. , 2009, , 367-403.		0
1049	Immune Tolerance. , 2009, , 653-664.		0

#	Article	IF	Citations
1051	Prevention of Islet Graft Rejection and Recipient Tolerization. , 2010, , 263-279.		0
1052	The Role of T-Cell Costimulatory Pathways in Regulation of Autoimmune Diabetes. Journal of Clinical & Cellular Immunology, 2011, , .	1.5	0
1053	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. , 2012, , 291-306.		0
1054	An Overview on Immunotherapy of Pancreatic Cancer. , 0, , .		0
1055	Genetics and Epigenetic in Systemic Lupus Erythematosus. , 0, , .		0
1056	PD-1 Expression in LPS-Induced Raw264.7 Cells Is Regulated via Co-activation of Transcription Factor NF-Î¹B and IRF-1. Korean Journal of Microbiology, 2013, 49, 301-308.	0.2	0
1057	B Cells in Cancer Immunology: For or Against Cancer Growth?. , 2015, , 47-60.		0
1058	Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2015, 126, 1461-1461.	1.4	2
1059	Immunotolerance and Immunoregulation. , 2017, , 39-47.		0
1060	Microtubule-Driven Stress Granule Dynamics Regulates Inhibitory Immune Checkpoints Expression in T Cells. SSRN Electronic Journal, 0, , .	0.4	0
1063	Immunology of Melanoma. , 2019, , 1-32.		0
1066	New view on alcoholic liver disease - potential role of PD1/PDL-1 pathway in the disease pathogenesis. Journal of Education, Health and Sport, 2019, 9, 121.	0.1	1
1067	B-Cells in Cancer Immunology: For or Against Cancer Growth?. , 2020, , 47-62.		0
1068	Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine antiâ€'PDâ€'1 administration. Molecular Medicine Reports, 2020, 22, 975-985.	2.4	3
1069	The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. Journal of Controlled Release, 2021, 340, 168-187.	9.9	20
1070	Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. Frontiers in Cardiovascular Medicine, 2021, 8, 740531.	2.4	10
1071	Immunology of Melanoma. , 2020, , 41-72.		0
1073	Companion Diagnostics and Clinical Biomarkers for Immunotherapy. , 2021, , 137-152.		0

#	Article	IF	Citations
1075	A 3D pancreatic tumor model to study T cell infiltration. Biomaterials Science, 2021, 9, 7420-7431.	5.4	17
1077	Cell Activation and Signaling in Lymphocytes. , 2020, , 133-161.		0
1078	Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy. , 2020, 3, 879-911.		16
1079	Radiotherapy and immunotherapy: open questions and future strategies. Trends in Cancer, 2022, 8, 9-20.	7.4	49
1080	New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. International Journal of Molecular Sciences, 2021, 22, 11898.	4.1	13
1081	Co-Receptors in the Positive and Negative Regulation of T-Cell Immunity. , 2008, , 221-245.		0
1084	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0
1086	Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells. Immunotherapy Advances, 2021, 1, ltaa001.	3.0	5
1087	The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes and Development, 2000, 14, 521-35.	5.9	293
1088	PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Molecular Vision, 2009, 15, 386-92.	1.1	32
1089	PD-1 blockade: A promising immunotherapy for HIV?. Cellscience, 2009, 5, 61-65.	0.3	15
1091	T cell costimulation and coinhibition: genetics and disease. Discovery Medicine, 2011, 12, 119-28.	0.5	21
1092	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. American Journal of Cancer Research, 2015, 5, 1553-7.	1.4	11
1093	Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells. Canadian Journal of Veterinary Research, 2017, 81, 147-154.	0.2	3
1094	B7-H3 role in the immune landscape of cancer. American Journal of Clinical and Experimental Immunology, 2017, 6, 66-75.	0.2	96
1095	Therapeutic targeting of immune checkpoints with small molecule inhibitors. American Journal of Translational Research (discontinued), 2019, 11, 529-541.	0.0	9
1096	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. International Journal of Clinical and Experimental Pathology, 2018, 11, 304-313.	0.5	7
1097	Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. International Journal of Clinical and Experimental Pathology, 2017, 10, 11754-11759.	0.5	1

#	Article	IF	Citations
1098	Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. American Journal of Cancer Research, 2020, 10, 688-703.	1.4	8
1099	Recombinant Expression and Purification of Extracellular Domain of the Programmed Cell Death Protein Receptor. Reports of Biochemistry and Molecular Biology, 2020, 8, 347-357.	1.4	0
1100	Infiltration of metastatic lymph nodes with PD-1 T cells is associated with improved disease-free and overall survival in resected N NSCLC. American Journal of Cancer Research, 2020, 10, 4435-4449.	1.4	0
1101	Impact of DNA Damage Responseâ€"Targeted Therapies on the Immune Response to Tumours. Cancers, 2021, 13, 6008.	3.7	5
1102	The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 759497.	2.8	4
1103	Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 767466.	3.7	13
1104	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	5.0	20
1105	Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model. Molecular Therapy - Oncolytics, 2022, 24, 77-86.	4.4	3
1106	PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review. Postepy Dermatologii I Alergologii, 2021, 38, 925-930.	0.9	6
1107	A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy. Applied Bionics and Biomechanics, 2022, 2022, 1-6.	1.1	5
1108	Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer. Translational Cancer Research, 2022, 11, 3-13.	1.0	3
1109	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
1110	Engineering interferons and interleukins for cancer immunotherapy. Advanced Drug Delivery Reviews, 2022, 182, 114112.	13.7	54
1111	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. Frontiers in Immunology, 2021, 12, 793992.	4.8	14
1112	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy Advances, 2022, 2, .	3.0	8
1113	Analytical methods for the detection of PD-1/PD-L1 and other molecules related to immune checkpoints. TrAC - Trends in Analytical Chemistry, 2022, 146, 116505.	11.4	3
1114	Metabolic Implications of Immune Checkpoint Proteins in Cancer. Cells, 2022, 11, 179.	4.1	15
1115	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 347-360.	4.1	9

#	Article	IF	Citations
1116	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Frontiers in Immunology, 2021, 12, 806043.	4.8	7
1117	Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. Clinical and Experimental Immunology, 2022, 207, 318-328.	2.6	3
1118	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell, 2022, 40, 255-276.	16.8	45
1119	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology, 2022, 106, 108617.	3.8	5
1120	Immunogenetics of Lupus Erythematosus. Advances in Experimental Medicine and Biology, 2022, 1367, 213-257.	1.6	1
1121	Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening. Journal of Chemical Information and Modeling, 2022, 62, 1236-1248.	5.4	2
1122	Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. Journal of Medicinal Chemistry, 2022, 65, 3879-3893.	6.4	55
1123	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. Cancer Management and Research, 2022, Volume 14, 1267-1281.	1.9	0
1124	Innate PD-L1 limits T cellâ€“mediated adipose tissue inflammation and ameliorates diet-induced obesity. Science Translational Medicine, 2022, 14, eabj6879.	12.4	22
1125	Tracking fluorescently labeled IL-15 and anti-PD-1 in the tumor microenvironment and draining lymph nodes. Journal of Immunological Methods, 2022, , 113253.	1.4	2
1126	Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1â€“Expressed CD8⁺ T Cells in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1166.	6.0	8
1127	Management of Regional Lymph Nodes in Head and Neck Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, , .	1.0	0
1128	Lithium salts as a treatment for COVID-19: Pre-clinical outcomes. Biomedicine and Pharmacotherapy, 2022, 149, 112872.	5.6	4
1129	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	2.4	8
1130	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	46.4	201
1131	Comprehensive phenotyping of murine lung resident lymphocytes after recovery from pneumococcal pneumonia. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, , .	1.5	2
1132	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. Frontiers in Pharmacology, 2022, 13, 774440.	3.5	5
1133	The role of cellular proteostasis in antitumor immunity. Journal of Biological Chemistry, 2022, 298, 101930.	3.4	6

#	Article	IF	Citations
1134	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nature Communications, 2022, 13, 2176.	12.8	18
1143	Alternate costimulatory molecules in T cell activation: differential mechanisms for directing the immune response. Histology and Histopathology, 2003, 18, 1195-204.	0.7	7
1144	The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells. Cancer Treatment and Research, 2022, 183, 275-285.	0.5	1
1145	Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 4717.	4.1	3
1146	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. Frontiers in Immunology, 2022, 13, 849515.	4.8	15
1147	Immune checkpoint inhibitor-related hypophysitis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101668.	4.7	11
1148	Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade. Diabetologia, 2022, 65, 1185-1197.	6.3	19
1149	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nature Reviews Urology, 2022, 19, 391-418.	3.8	20
1150	Interleukin-10 Delays Viral Clearance in the Placenta and Uterus of Mice With Acute Lymphocytic Choriomeningitis Virus Infection During Pregnancy. Frontiers in Virology, 2022, 2, .	1.4	5
1151	PDâ€1 mediates decidual Î³Î´ T cells cytotoxicity during recurrent pregnancy loss. American Journal of Reproductive Immunology, 2022, 88, .	1.2	4
1152	GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. Journal of Experimental Medicine, 2022, 219, .	8.5	4
1153	ROLE OF MONOCLONAL ANTIBODIES AGAINST THE PROGRAMMABLE DEATH (PD-1) RECEPTOR OF T-CELLS IN TARGETED THERAPY OF MELANOMA. Eurasian Journal of Applied Biotechnology, 2018, , .	0.1	0
1154	PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy. Frontiers in Immunology, 2022, 13, .	4.8	5
1155	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Frontiers in Immunology, 0, 13, .	4.8	3
1156	Targeted therapies in nonâ€small cell lung cancer and the potential role of AI interventions in cancer treatment. Biotechnology and Applied Biochemistry, 2023, 70, 344-356.	3.1	3
1157	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. Clinical Science, 2022, 136, 771-785.	4.3	2
1158	Subsets of Tissue CD4 T Cells Display Different Susceptibilities to HIV Infection and Death: Analysis by CyTOF and Single Cell RNA-seq. Frontiers in Immunology, 0, 13, .	4.8	3
1159	Key differences between anti-PD-1/PD-L1 inhibitors. Meditsinskiy Sovet, 2022, , 22-28.	0.5	0

#	Article	IF	Citations
1160	Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome. Immunologic Research, 2022, 70, 698-707.	2.9	9
1161	Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Research, 2022, 82, 2593-2609.	0.9	5
1162	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, .	2.8	19
1163	InÂvivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer. Biochemical and Biophysical Research Communications, 2022, 620, 105-112.	2.1	6
1164	Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer. Mathematical Biosciences, 2022, 350, 108868.	1.9	3
1166	Immunotherapy of Metastatic Melanoma. , 0, , .		0
1167	The Role of the Immune System in the Development of Endometriosis. Cells, 2022, 11, 2028.	4.1	40
1168	Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry, 2022, 65, 8596-8685.	6.4	29
1169	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. Journal of Controlled Release, 2022, 349, 425-433.	9.9	2
1170	PD-L1 expression in EBV-associated gastric carcinomas. Arkhiv Patologii, 2022, 84, 5.	0.2	2
1171	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. Human Antibodies, 2022, , 1-20.	1.5	0
1172	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. Current Medicinal Chemistry, 2023, 30, 3215-3237.	2.4	3
1173	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 202-209.	1.6	5
1174	Cancer vaccines: the next immunotherapy frontier. Nature Cancer, 2022, 3, 911-926.	13.2	207
1176	Pregnancy Imparts Distinct Systemic Adaptive Immune Function. American Journal of Reproductive Immunology, 0, , .	1.2	3
1177	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. Clinics and Practice, 2022, 12, 653-671.	1.4	8
1178	Engineered Macrophage-Membrane-Coated Nanoparticles with Enhanced PD-1 Expression Induce Immunomodulation for a Synergistic and Targeted Antiglioblastoma Activity. Nano Letters, 2022, 22, 6606-6614.	9.1	34
1179	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. Bioorganic and Medicinal Chemistry, 2022, 73, 117001.	3.0	9

#	Article	IF	Citations
1180	The tumor microenvironment. , 2022, , 31-58.		7
1181	Cardiovascular complications of immune checkpoint inhibitors for cancer. European Heart Journal, 2022, 43, 4458-4468.	2.2	30
1182	High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. Cancer Gene Therapy, 0, , .	4.6	0
1183	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	3.7	6
1184	Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. Journal of Clinical Investigation, 2022, 132, .	8.2	9
1185	The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
1187	Immune cells and their inflammatory mediators modify Î² cells and cause checkpoint inhibitorâ€“induced diabetes. JCI Insight, 2022, 7, .	5.0	17
1188	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology, 2022, 11, .	4.6	28
1189	TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy. , 2022, 39, .		3
1190	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, .	4.8	8
1191	Costimulation blockade and Tregs in solid organ transplantation. Frontiers in Immunology, 0, 13, .	4.8	5
1192	A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). OncoImmunology, 2022, 11, .	4.6	10
1193	Mathematical modeling for the combination treatment of IFN-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="d1e4854" altimg="si118.svg"><mml:mi>Î³</mml:mi></mml:math> and anti-PD-1 in cancer immunotherapy. Mathematical Biosciences, 2022, 353, 108911.	1.9	4
1194	AKT Isoforms in the Immune Response in Cancer. Current Topics in Microbiology and Immunology, 2022, , 349-366.	1.1	0
1195	PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. Pathologica, 2022, 114, 352-364.	3.4	13
1196	Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. Metabolites, 2022, 12, 966.	2.9	2
1198	Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function. British Journal of Cancer, 2022, 127, 2175-2185.	6.4	11
1199	Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles. Frontiers in Immunology, 0, 13, .	4.8	2

#	Article	IF	Citations
1200	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. Animals, 2022, 12, 2661.	2.3	2
1201	Phenotypic profiling of <scp>CD279</scp> and <scp>CD185</scp> level on helper T cells in patients with autoimmune hepatitis. Scandinavian Journal of Immunology, 0, , .	2.7	0
1202	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines, 2022, 10, 1673.	4.4	1
1203	The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation. Cancers, 2022, 14, 5374.	3.7	4
1204	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
1205	Tumor immune checkpoints and their associated inhibitors. Journal of Zhejiang University: Science B, 2022, 23, 823-843.	2.8	9
1206	Autoimmunity: Are we asking the right question?. Frontiers in Immunology, 0, 13, .	4.8	6
1207	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
1208	Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. International Immunology, 2023, 35, 67-77.	4.0	0
1209	Until programmed death do us tolerant. Journal of Clinical Investigation, 2022, 132, .	8.2	0
1210	CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways. Cancers, 2022, 14, 5610.	3.7	5
1211	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. Biomedicine and Pharmacotherapy, 2023, 157, 114057.	5.6	5
1212	Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. Seminars in Immunology, 2023, 65, 101703.	5.6	11
1213	Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization. Neoplasia, 2023, 36, 100867.	5.3	9
1214	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0
1215	Targeting PIM Kinases to Improve the Efficacy of Immunotherapy. Cells, 2022, 11, 3700.	4.1	4
1217	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Frontiers in Immunology, 0, 13, .	4.8	6
1218	Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80. Journal of Biological Chemistry, 2023, 299, 102769.	3.4	4

#	Article	IF	Citations
1219	The effect of Wnt/Î²-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. Oncology Research, 2022, 30, 99-116.	1.5	7
1220	Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. Frontiers in Immunology, 0, 13, .	4.8	2
1221	Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?. Current Oncology, 2023, 30, 1267-1274.	2.2	1
1222	TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Communications Biology, 2023, 6, .	4.4	5
1223	Immune checkpoint inhibitors and reproductive failures. Journal of Reproductive Immunology, 2023, 156, 103799.	1.9	11
1224	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. Cancers, 2023, 15, 246.	3.7	8
1225	Emerging therapeutic targets of genitourinary tumors. , 2023, , 181-192.		0
1226	PD-1 and PDL-1 gene expression in nasal polyp tissue from patients with asthma exacerbated by non-steroidal anti-inflammatory drugs correlates with the severity of the disease. Otolaryngologia Polska, 2023, 77, 1-5.	0.6	0
1227	Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	9
1229	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	5
1230	Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. Current Cancer Therapy Reviews, 2024, 20, 53-99.	0.3	0
1231	Programmed death ligand 1 regulates epithelialâ€“mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/Î²â€catenin signaling pathway. Cancer Science, 2023, 114, 2265-2276.	3.9	2
1232	Regulation of programmed death ligand 1 expression by interferonâ€Î³ and tumour necrosis factorâ€Î± in canine tumour cell lines. Veterinary and Comparative Oncology, 0, , .	1.8	0
1233	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer, 2023, 22, .	19.2	29
1234	Advances in immune checkpoint inhibitors induced-cardiotoxicity. Frontiers in Immunology, 0, 14, .	4.8	2
1235	Î²3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-Î³-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. Cancer Gene Therapy, 2023, 30, 890-904.	4.6	5
1236	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. International Journal of Molecular Sciences, 2023, 24, 4786.	4.1	0
1237	Role of regulation of PD-1 and PD-L1 expression in sepsis. Frontiers in Immunology, 0, 14, .	4.8	6

#	Article	IF	Citations
1238	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1239	A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2023, 29, 2052-2065.	7.0	8
1241	The usage of Pembrolizumab in Metastatic Urothelial Carcinoma. , 0, 36, 331-340.		0
1242	Novel technologies for applying immune checkpoint blockers. International Review of Cell and Molecular Biology, 2024, , 1-101.	3.2	2
1243	Expression and function of CD51 on CD8 T cells as an immunomodulatory target. Biochemical and Biophysical Research Communications, 2023, 661, 56-63.	2.1	0
1244	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathology Research and Practice, 2023, 246, 154470.	2.3	0
1245	Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression. Cancer Immunology, Immunotherapy, 0, , .	4.2	1
1246	Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model. Experimental Hematology, 2023, 123, 56-65.	0.4	1
1247	Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nature Reviews Immunology, 2023, 23, 682-695.	22.7	24
1248	Regulation of CD8 Tâ€cell signaling, metabolism, and cytotoxic activity by extracellular lysophosphatidic acid. Immunological Reviews, 2023, 317, 203-222.	6.0	2
1249	PD-1/PD-L1 axis in organ fibrosis. Frontiers in Immunology, 0, 14, .	4.8	3
1250	Development of anti-feline PD-1 antibody and its functional analysis. Scientific Reports, 2023, 13, .	3.3	0
1251	Highly multiplexed immune profiling throughout adulthood reveals kinetics of lymphocyte infiltration in the aging mouse prostate. Aging, 2023, 15, 3356-3380.	3.1	0
1252	New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). International Journal of Oncology, 2023, 63, .	3.3	3
1253	Determination of Tr1 cell populations correlating with distinct activation states in acute IAV infection. Mucosal Immunology, 2023, , .	6.0	1
1254	Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review. Frontiers in Oncology, 0, 13, .	2.8	2
1256	Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer. Chinese Medicine, 2023, 18, .	4.0	2
1257	Metformin as a booster of cancer immunotherapy. International Immunopharmacology, 2023, 121, 110528.	3.8	3

#	Article	IF	Citations
1258	Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. Frontiers in Oncology, 0, 13, .	2.8	0
1259	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in sheep. Veterinary Immunology and Immunopathology, 2023, 261, 110609.	1.2	0
1260	Cumulative effects of weakly repressive regulatory regions in the 3â€™ UTR maintain PD-1 expression homeostasis in mammals. Communications Biology, 2023, 6, .	4.4	1
1261	METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment. Scientific Reports, 2023, 13, .	3.3	1
1262	Very Unstable Genetics: How the Confluence of Microsatellite Instability and Immunotherapy Revolutionized the Treatment of Colon Cancer. Digestive Diseases and Sciences, 0, , .	2.3	0
1263	A Review of the Impact of PD-L1 Expression on the Prognosis of Small Cell Lung Cancer. Journal of Biosciences and Medicines, 2023, 11, 1-8.	0.2	0
1264	Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review. Uspehi Molekularnoj Onkologii, 2023, 10, 70-77.	0.3	0
1265	Friend or Foe â€“ Tc17 cell generation and current evidence for their importance in human disease. , 0, , .		0
1266	The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge. Frontiers in Immunology, 0, 14, .	4.8	1
1267	Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsingâ€“remitting multiple sclerosis. Brain Communications, 2023, 5, .	3.3	1
1268	Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2â€²-dihalogen-substituted) Tj ETQq0 0 0 rgBT /Overlock 10 Chemistry, 2023, 66, 10579-10603.	6.4	5
1269	A role for platelets in metabolic reprogramming of tumor-associated macrophages. Frontiers in Physiology, 0, 14, .	2.8	2
1271	Divergent CD4+ T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients. Frontiers in Immunology, 0, 14, .	4.8	0
1272	Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies. Expert Opinion on Drug Safety, 2023, 22, 909-919.	2.4	1
1273	The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Frontiers in Immunology, 0, 14, .	4.8	1
1274	A Review on Inflammasomes and Immune Checkpoints in Pre-Eclampsia Complicated with Tuberculosis and Human Immune Deficiency Virus. International Journal of Environmental Research and Public Health, 2023, 20, 6627.	2.6	0
1275	Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers, 2023, 15, 4574.	3.7	4
1276	Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells. Frontiers in Immunology, 0, 14, .	4.8	1

#	Article	IF	Citations
1277	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
1278	The tumour-promoting role of protein homeostasis: Implications for cancer immunotherapy. Cancer Letters, 2023, 573, 216354.	7.2	2
1279	Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 3727-3738.	4.2	3
1280	Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment. Mathematical Biosciences, 2023, 365, 109072.	1.9	0
1281	Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms. Journal of Bone Oncology, 2023, 43, 100505.	2.4	1
1282	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	4.2	4
1283	Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor. ACS Omega, 0, , .	3.5	0
1285	Synergistic effects of immune checkpoints and checkpoint inhibitors in inflammatory neuropathies: Implications and mechanisms. Journal of the Peripheral Nervous System, 2024, 29, 6-16.	3.1	0
1286	Pathogenicity of functionally activated PD-1+CD8+ cells and counterattacks by muscular PD-L1 through IFNÎ³ in myositis. Journal of Autoimmunity, 2024, 142, 103131.	6.5	0
1287	Expression and clinical implications of HLA-G and PD-L1 following kidney transplantation: A cohort study. Medicine (United States), 2023, 102, e36053.	1.0	0
1288	Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy. Journal of Pharmaceutical Investigation, 0, , .	5.3	0
1289	Molecular interactions of antibodies with PD-1/PD-L1 proteins. Immunotherapy, 0, , .	2.0	0
1291	Does the use of low-molecular-weight heparin during pregnancy change the expression of PD-1 and PDL-1 in women with recurrent pregnancy loss?. TâŠÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2023, 20, 269-274.	0.8	0
1292	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. British Journal of Cancer, 2023, 129, 1409-1416.	6.4	4
1293	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
1294	Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1. Journal of Immunology, 0, , .	0.8	1
1295	IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer. Journal of Theoretical Biology, 2024, 579, 111704.	1.7	0
1297	Beyond Inhibition Against PD-1/PD-L1 Pathway: Development of PD-L1 Inhibitors Targeting Internalization and Degradation of PD-L1. RSC Medicinal Chemistry, 0, , .	3.9	0

#	Article	IF	Citations
1299	Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. International Journal of Molecular Sciences, 2024, 25, 433.	4.1	0
1300	Predictive and prognostic biomarkers in gastrointestinal tract tumours. Pathology, 2024, 56, 205-213.	0.6	1
1301	Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors. Life Science Alliance, 2024, 7, e202302368.	2.8	0
1302	Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets. Blood Science, 2024, 6, e00181.	0.9	0
1304	Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review. Cancers, 2024, 16, 523.	3.7	0
1305	NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy. Frontiers in Immunology, 0, 15, .	4.8	0
1306	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American Journal of Clinical Dermatology, 2024, 25, 407-419.	6.7	0
1308	The role of programmed death receptor (PDâ€)1/PDâ€ligand (L)1 in periodontitis and cancer. Periodontology 2000, 0, , .	13.4	0
1309	Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia. Cell Death and Disease, 2024, 15, .	6.3	0
1310	A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. OncoImmunology, 2024, 13, .	4.6	0
1311	PD-1 regulation in immune homeostasis and immunotherapy. Cancer Letters, 2024, 588, 216726.	7.2	0
1312	Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors. Frontiers in Immunology, 0, 15, .	4.8	0
1313	Anti-Tumor Potential of Post-Translational Modifications of PD-1. Current Issues in Molecular Biology, 2024, 46, 2119-2132.	2.4	0
1314	Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach. Frontiers in Immunology, 0, 15, .	4.8	0
1315	Targeting pro-inflammatory TÂcells as a novel therapeutic approach to potentially resolve atherosclerosis in humans. Cell Research, 0, , .	12.0	0
1316	Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. Cancers, 2024, 16, 1237.	3.7	0